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ABSTRACT:                                                                                                                                
Cancer cells exhibit altered metabolism characterized by increased glucose and glutamine 
uptake. Altered utilization of these substrates directly contributes to O-linked-β-N-
acetylglucosamine (O-GlcNAc) modifications on intracellular proteins. Multiple cancers contain 
elevated total O-GlcNAcylation, in part, by increasing O-GlcNAc transferase (OGT) levels, the 
enzyme that catalyzes this modification. Although cancer cells require OGT for oncogenesis, it is 
not clear how tumor cells regulate OGT expression and O-GlcNAcylation.  Here, we show that 
the PI3K/mTOR/MYC pathway is required for elevation of OGT and O-GlcNAcylation in breast 
cancer cells as treatment with PI3K and mTOR inhibitors reduced OGT protein expression and 
decreased levels of overall O-GlcNAcylation. Downstream of mTOR, the oncogenic 
transcription factor c-MYC is required and sufficient for increased OGT protein expression in an 
RNA-independent manner and c-MYC regulation of OGT in cancer cells requires the expression 
of c-MYC target HSP90A. Mammary tumor epithelial cells derived from MMTV-c-myc 
transgenic mice contain elevated OGT and global O-GlcNAcylation and OGT inhibition in these 
tumor cells induces apoptosis. In an attempt to further address consequences of elevated O-
GlcNAcylation in breast cancer, we performed comprehensive metabolomics. Metabolomics 
analysis revealed that reducing OGT levels in breast cancer cells altered a number of metabolic 
pathways including amino acids and nucleotides, however, the largest change was seen in fatty 
acid metabolites. We show that O-GlcNAcylation regulates the transcription factor sterol 
regulatory element binding protein 1 (SREBP-1) and its transcriptional targets, critical enzymes 
involved in lipid synthesis. OGT regulates SREBP-1 protein expression and stability/degradation 
via AMP Activated protein kinase (AMPK). SREBP-1 is critical for OGT-mediated regulation of 
cell survival and of lipid synthesis, as overexpression of SREBP-1 rescues lipogenic defects  
                  xiv 
associated with OGT suppression, and tumor growth in vitro and in vivo. We also find that OGT  
regulates these factors in lactating mammary glands, highly lipogenic normal tissue. These   
results unravel a previously unidentified link between O-GlcNAcylation, lipid metabolism and 
the regulation of SREBP-1 in cancer. These finding suggests OGT may be a novel therapeutic 
target for the treatment of lipid-dependent cancers. 
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CHAPTER 1: O-GLCNACYLATION AND OGT 
1.1 Introduction to O-GlcNAcylation 
Many processes exist within a cell to guarantee homeostasis in response to the 
availability of required cellular sustenance. A cells response to adequate or inadequate 
nutrient supply dictates its survival and appropriate epigenetic, genetic, transcriptional, 
translational and post-translational machinery must work in harmony to coordinate this 
response correctly. In the past years, there has been much interest in all of the regulatory 
aspects of this response, especially as they exist in metabolic pathologies where nutrient 
responsive pathways are dysregulated. With respect to post-translational modifications, 
much attention has been given to phosphorylation which serves as an important 
modification not only in the context of nutrient changes but in virtually every alteration 
inside and outside of the cell. One less well studied modification that is now recognized 
as an important contributor to many cellular processes, is O-linked β N-
acetylglucosaminylation (O-GlcNAcylation). This modification serves as a powerful 
regulator of cellular biology and behavior, particularly in response to nutrients, as it is 
directly dependent on flux through glycolysis and therefore glucose levels in the cell. 
Although the majority of glucose taken up by the cell is metabolized through the 
glycolytic pathway, 3-5% is diverted into the hexosamine biosynthetic pathway (HBP) 
[1], where it is converted to glucosamine-6-phosphate (GlucN-6-P) by the rate limiting 
enzyme glutamine:fructose-6-phosphate amidotransferase (GFAT) [2] (Figure 1).  
Subsequently, GlucN-6-P is converted to uridine-5-diphosphate-N-acetylglucosamine 
(UDP-GlcNAc), which then serves as a substrate for N-linked glycosylation of proteins 
in the ER and Golgi as well as O-linked glycosylation of nuclear and cytoplasmic 
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proteins [3].  The enzyme O-GlcNAc transferase (OGT) uses UDP-GlcNAc as a substrate 
to add O-linked sugar moieties onto serine and threonine residue hydroxyl groups of a 
diverse range of nuclear and cytoplasmic proteins (Figure 2) [4, 5]. The production of 
UDP-GlcNAc requires the contributions of glutamine from amino acid metabolism, 
acetyl-CoA from fatty acid metabolism, and UTP from nucleotide metabolism, further 
demonstrating how in tune this modification is to cellular nutrient status [6]. The process 
of O-GlcNAc cycling is highly dynamic. The addition and removal of O-GlcNAc is 
performed solely by the two enzymes OGT and O-GlcNAcase (OGA), respectively, a 
striking contrast to the over 600 human kinases and phosphatases required for 
phosphorylation [7]. The addition of this unique O-linked sugar is an important post-
translational modification (PTM)  with the ability to influence many biological processes 
by altering protein stability, interaction capabilities, degradation and/or stability and even 
phosphorylation status [8]. The role of O-GlcNAc extends to diverse cellular processes, 
as its known targets include a wide range of proteins including transcription factors, 
signaling proteins and receptors [9]. O-GlcNAcylation plays an important role in normal 
biology and is deregulated in a wide range of pathologies including cardiovascular and 
neurodegenerative diseases as well as metabolic syndromes such as diabetes [10] and 
cancer which will be covered more thoroughly later.  
1.1.1 OGT/OGA proteins  
O-GlcNAc modifications are added to hydroxyl groups of serine and threonine of target 
proteins by the glycosyltransferase OGT. This enzyme was identified in the early 1990s 
[11] and was cloned in 1997. Human full-length OGT protein was determined to contain 
13 N-terminal tetratricopeptide repeats (TPRs), a number which varies in other isoforms 
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and organisms (Figure 3) [11]. In 2004 OGT protein crystal structure was solved 
revealing superhelical structures formed by the TPRs as well as demonstrating the ability 
of OGT to form a homodimer [12]. The structure of the C-terminal catalytic domain of 
OGT was solved years later and showed that this domain was a lobular structure. There 
remains structurally undetermined portions that have been implicated in interaction with 
membranes based on the prevalence of  basic residues [6]. The C-terminal portion of 
OGT also contains a phosphoinositide binding domain (PPO) demonstrated to have 
activity in protein-lipid binding to several lipid species [13]. OGT is not a promiscuous 
glycosyltransferase, however, the mechanism of recognition of target proteins for 
modification by OGT remains unknown. TPR domains are known to function in protein-
protein interaction and are required for recognition of target proteins, however no strict 
consensus sequence for modification exists. Truncation of these domains demonstrated a 
loss in ability to bind target proteins [14]. Although the substrate protein may be bound 
by the TPR repeats, the structure of OGT imposes restrictions that define some sequence 
specificity [15]. Recognition still remains mysterious, but these studies of structure have 
provided valuable information about reaction kinetics demonstrating that OGT first binds 
UDP-GlcNAc, then binds substrate peptides before a reaction occurs [6].   
This enzyme has recently been shown to perform a non-glycosyltransferase 
protease role by two groups [16, 17]. OGT was found to cleave the transcription factor 
host-cell factor1 (HCF-1), important in cell-cycle progression. Cleavage of this factor is 
required to ensure effective and appropriate cytokinesis but despite the importance OGT 
may play mechanistically in this event, lack of cleavage and ogt deletion do not 
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phenocopy in mammalian cells [6].  OGT is also implicated in scaffolding due to its 
occupation in several stable protein complexes in cells [6].   
1.1.2 The function of OGT and O-GlcNAcylation in biology 
In normal biology OGT and O-GlcNAcylation play critical roles in cell differentiation, 
growth and development as deletion of the ogt gene, which is located in the mammalian 
X chromosome, is lethal in ES cell culture and mouse embryogenesis [18]. The first 
connection made between OGT mutation and human pathology was just elucidated in an 
X chromosome exome screen. Two separate mutations (one missense and one SNP) in 
the TPR domain of OGT, resulting in decreased protein stability or altered protein-
protein interactions, were linked to X-linked intellectual disabilities (XLID) [19]. Due to 
its requirement in development evident by embryonic lethality mentioned above, 
conditional knockout of ogt is the only means to study the role of OGT in different adult 
tissues. The few studies utilizing conditional deletion of ogt have examined the role of O-
GlcNAcylation in beta cells, the placenta, and T cells, the latter examining both normal 
development and malignant transformation. Conditional deletion of ogt was shown to 
perturb ER homeostasis, and crucial signaling in beta cells resulting in beta cell failure 
and diabetes in mice [20]. ER stress induced in this model is similar to the effects seen 
upon inhibition of OGT in breast cancer cells which our lab has previously examined 
[21]. It is not surprising that OGT expression is required for beta cell survival as these 
cells, much like cancer cells, are incredibly metabolic. Targeted deletion of ogt in the 
placenta mimicked phenotypes found in early prenatal stress (EPS) consisting of changes 
in gene expression which alter response to both endocrine and inflammatory signaling. 
Offspring of adults containing ogt placental deletion had lower body weight and 
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increased hypothalamic-pituitary-adrenal stress responsiveness. This study strongly 
implicates OGT expression as an important indicator of maternal stress and a regulator in 
programming of offspring metabolic- and neuro-development [22].  Deletion of ogt in  
progenitor T cells showed that OGT expression was required for T cell development in 
vivo [23]. OGT expression was also required for transformation of T cell progenitors into 
T cell acute lymphoblastic leukemia using a different mouse model in the same study, 
highlighting the importance of this factor in normal T cell biology as well as cancer 
development in this particular model [23]. This study serves as the first to address the 
requirement of ogt gene expression in a genetic mouse model of cancer. OGA was 
originally identified in meningioma as an autoantigen and named MGEA5 however, was 
later determined to act as a hydrolase removing O-GlcNAc modifications from proteins 
[24, 25]. It was found that the N-terminus of this protein contains the domain responsible 
for its O-GlcNAcase activity and a C-terminal domain that resembles a histone 
acetyltransferase (HAT). While this HAT-like domain has been controversial, recently 
several papers have supported the idea that OGA has HAT activity [24, 26, 27]. Unlike 
ogt deletion which was embryonic lethal, genetic deletion of mgea5 (OGA) is perinatal 
lethal and although heterozygous animals were found to be viable, they exhibited gross 
changes in both transcription and metabolism [28].   
The enzymatic activity of OGT is responsive to levels of UDP-GlcNAc which can 
vary greatly based on tissue and also change during cellular and tissue conditions such as 
inflammation and nutrient availability [7]. It has recently been suggested that O-
GlcNAcylation may serve as a signal on proteins during translation as a mark of 
protection from proteasomal degradation [29].  
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It is apparent that OGT and O-GlcNAcylation require strict regulation in normal 
physiology, as aberrations are found in a variety of pathologies (Figure 4). It has 
profound effects on many cellular processes including general mechanisms of gene 
expression. It is presumed that OGT can regulate transcriptional activation as it was 
found to directly modify Histone 2B (H2B) S112 which correlated with sites of active 
transcription distributed over multiple chromosomes [30]. OGT was found to interact 
with and directly modify several Ten-eleven translocation enzymes (TET) family 
members (TET1, TET2, and TET3) (Figure 5) [31]. These enzymes act to demethylate 5-
methocytosine (5mC) DNA bases. O-GlcNAcylation has also been determined to affect 
methylation specifically through modification of zeste homolog 2 (EZH2) which allows 
for the methylation modification H3K27me3. Transcriptionally silenced chromatin is 
found to contain this trimethylation modification on histone 3 [32]. Transcription is 
regulated on a circadian basis within cells which is also found to be controlled by O-
GlcNAcylation. O-GlcNAcylation functions to stabilize the clock proteins 
ARNTL/BMAL1 and CLOCK which in turn mediate transcription of genes such as 
PER1/2 and CRY1/2 which are also important core components to the regulation of the 
circadian clock (Figure 5) [33]. OGT additionally plays a role in repression of 
transcription through its interaction with the corepressor mSin3A at promoter sites [34]. 
All of these mechanisms by which OGT and O-GlcNAcylation act to enhance or decrease 
gene transcription within cells demonstrate the importance of controlling a balance of 
levels of both OGT and O-GlcNAcylation to ensure proper cellular function. It is clear 
from many studies showing altered levels of O-GlcNAcylation in disease state that too 
little or too much compromises normal function and behavior (Figure 4).   
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1.1.3 Regulation of OGT  
While it is clear that both expression and activities of OGT and OGA are 
responsible for levels of O-GlcNAcylation on target proteins, the affinities of these 
proteins for O-GlcNAcylated substrate proteins has led researchers to believe that the 
stronger determinant and therefore the more crucial governing factor is OGT [35]. Since 
OGT is altered in many disease states, it is imperative to understand what controls OGT 
expression. The factors involved in transcriptional activation and repression of OGT are 
largely unknown, although recently several regulatory factors were identified.  OGT 
mRNA expression was upregulated in response to overexpression of the transcription 
factor Elk1, but its occupancy on the promoter of OGT or ability to bind this region were 
not examined in this study [36]. E2F Transcription Factor 1 (E2F) was found to bind the 
promoters of both OGT and OGA and has a role in repressing OGT expression in an Rb-
1 dependent manner [37]. In terms of cancer, specifically breast cancer, several reports 
have examined mRNA expression. While others have reported a correlative change in 
OGT and OGA mRNA expression with progression of breast ductal carcinoma indicating 
an increase in OGT and decrease in OGA expression as grades progress [38], our own 
comparison between normal tissue and several subtypes of breast cancer showed no 
change in OGT mRNA expression [21]. Expression of OGT mRNA was not found to 
correlate to overall or metastasis-free survival in breast cancer patients or to show 
significant changes between normal patient breast samples and diseased breast of various 
subtypes based on our analysis [21].  
OGT protein can be modified by direct O-GlcNAcylation and tyrosine 
phosphorylation however there are likely other PTMs not yet identified on this protein 
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[39]. OGT is turned over via proteasomal degradation requiring ubiquitination on OGT 
[40].  Beyond these modifications, little is known about the regulation of OGT protein 
expression. In this thesis we will specifically address regulation of OGT protein in breast 
cancer. 
1.2 O-GlcNAcylation and OGT in disease 
1.2.1 OGT and neurodegenerative disease 
As mentioned above, because of the paramount role O-GlcNAcylation seems to play in 
maintaining homeostasis of a variety of important cellular activities and systems, and due 
to its utilization of and requirement for glucose, it is only natural that O-GlcNAcylation 
would be investigated in the context of the central nervous system (CNS) and that many 
proteins would be highly O-GlcNAcylated. When Trinidad et. Al examined O-
GlcNAcylation in the murine synaptasome they determined 19% of proteins were O-
GlcNAcylated. The idea that disruption of glucose metabolism could contribute to 
diseases of the brain, specifically Alzheimer’s disease (AD), along with the high 
abundance of O-GlcNAcylated proteins in brain has led many to investigate a role for 
OGT and O-GlcNAc in this pathology. The neuronal glucose transporter GLUT3 is 
decreased in AD brains leading to compromised glucose metabolism [41]. It was 
determined that a microtubule associated protein key to the AD phenotype, tau, which 
becomes aggregated in diseased circumstances, is itself O-GlcNAcylated [42]. It was also 
determined that in AD, tau is hyperphosphorylated and O-GlcNAcylated less [43, 44]. It 
is now hypothesized that the alterations in glucose utilization decrease O-GlcNAcylation 
on tau and increase its hyperphosphorylation. These conditions are consistent with tau 
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pathology which correlates with severity of dementia [43]. Another neurodegenerative 
disease, amyotrophic lateral sclerosis (ALS) may also be linked to changes in O-
GlcNAcylation. ALS is characterized by accumulation of neurofilamental proteins NF-L 
and NF-M (the light and medium chains of neurofilament proteins) which are 
phosphorylated as well as O-GlcNAcylated [45].  In this context, O-GlcNAcyaltion could 
play a neuroprotective role similar to that hypothesized in AD [46]. 
1.2.2 OGT and diabetes  
Yet another pathology consisting of altered energy and glucose metabolism is diabetes. 
Determining the unknown underlying mechanisms responsible for the development of 
this disease is important because 7.8 % of the United States population is diagnosed with 
diabetes [47]. Type 2 diabetes is characterized by elevated blood glucose and insulin 
insensitivity. A normal liver should activate insulin receptor when bound to insulin, 
recruiting insulin receptor substrate (IRS1 or IRS2). Ultimately this activation results in 
translocation of the glucose transporter GLUT4 to the membrane through PI3K/AKT 
[47]. IRS1 is O-GlcNAcylated on at least three sites resulting in altered phosphorylation 
status of this protein and subsequent attenuation of insulin signaling [48]. OGT also O-
GlcNAcylates PI3K and AKT [47]. It is suggested that O-GlcNAc could be a biomarker 
of prediabetes since elevated blood glucose levels could increase levels of O-
GlcNAcylation in red blood cells [49].  
1.2.3 OGT and Cancer  
Elevated O-GlcNAcylation has been observed in various cancer types, and inhibiting O-
GlcNAcylation reduces several cancer phenotypes. The Warburg hypothesis (discussed 
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more thoroughly in later chapters) states that cancer cells display altered metabolic 
features in order to support their rapid growth and biosynthetic demands. It is also 
characterized by increased glycolytic flux, even in the presence of oxygen, in order to 
synthesize necessary building blocks required by rapidly growing cells [50]. It is 
currently understood that this shift is supported by oncogenic mutations allowing not only 
for increased uptake of metabolites such as glucose but also for the continual 
consumption of such metabolites in synthetic processes [50]. Recently, much attention 
has been given to understanding the therapeutic potential of targeting metabolic pathways 
in cancer, as these highly proliferative cells are incredibly dependent upon these 
pathways for their sustained growth and survival.  
This increased glycolytic flux observed in cancer cells feeds not only glycolysis but to 
other glucose dependent pathways as well, such as the Hexosamine Biosynthetic Pathway 
(HBP), which as described above, provides the substrate to OGT for O-GlcNAc 
modification [4, 51]. It is not surprising that a nutrient sensitive modification would be 
altered in conditions where more glucose and glutamine are available and utilized 
differently. O-GlcNAcylation provides a driver of tumorigenic phenotypes as many 
modified proteins have roles in oncogenesis [52]. These proteins include well known and 
highly influential factors such as; c-Myc, AKT, PI3K, SP1 and p53 [53-56]. When 
examining the effects of this modification on oncogenic drivers, it is important to 
remember that O-GlcNAcylation can modulate a proteins function by altering stability, 
localization, protein-protein interaction, phosphorylation status, and/or DNA binding 
ability [57].  With regard to biological results, modulation of cellular O-GlcNAc levels 
has been linked to altered cellular development, mitotic progression, growth and survival 
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patterns [58]. Hyper-O-GlcNAcylation appears to be a common feature of various 
cancers as elevation of OGT and this modification have been observed in breast [59], 
prostate [60], lung, colorectal, liver, and pancreatic malignancies [61]. It also appears that 
this modification exerts influence over many hallmarks of cancer including angiogenesis, 
invasion, proliferation, and survival (Table 1).  
Our lab was the first to show that both O-GlcNAcylation and OGT levels are increased in 
breast cancer cells (Table 1) and that reduction of OGT and O-GlcNAcylation in cancer 
cells results in decreased growth and metastasis in vivo [59, 60]. Inhibition of OGT and 
O-GlcNAcylation was shown to activate the cellular nutrient sensor 5’ AMP-activated 
protein kinase (AMPK) and induce apoptosis in breast cancer cell lines through ER stress 
pathway activation. However, reducing OGT levels in normal immortalized mammary 
epithelial cells had no effect on these pathways. Thus, cancer cells are more sensitive to 
inhibition of O-GlcNAcylation [21].  
As mentioned above, critical regulators of oncogenesis, including the c-Myc 
oncogene [53], the tumor suppressor p53 [63], and viral oncoprotein SV40 large T 
antigen [64], have been previously shown to be O-GlcNAcylated lending the idea that O-
GlcNAcylation may play a key role in the pathogenesis of tumors [65, 66]. A critical role 
of O-GlcNAcylation on NF- [67] function, combined with work in our lab provided 
the first evidence that total O-GlcNAcylation and OGT was required for tumor growth in 
vitro and in vivo [59]. A number of groups have subsequently shown that OGT and O-
GlcNAcylation levels are elevated in various different epithelial cancers including breast 
[68, 69], prostate [60, 70], lung [71], colon [72], liver [73], bladder [74] as well as in 
chronic lymphatic leukemia (CLL) (Table 1) [75]. A critical role for O-GlcNAcylation in 
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cancer metabolism emerged as OGT was found to be required for expression of a major 
glycolytic driver, hypoxia-inducible factor (HIF-1α), along with its transcriptional target 
glucose transporter 1 (GLUT1) [21, 59, 62].  This mechanism is critical for breast cancer 
cell survival both in vitro and in vivo [76]. O-GlcNAcylation has also recently been 
shown to influence the Pentose Phosphate Pathway (PPP) through regulation of 
Phosphofructokinase 1 activity [71]. In some cancers, increased total O-GlcNAcylation 
may be due to increased OGT levels and/or decreased OGA levels as seen in breast [76, 
77], liver [73] and colon [78] cancers. Specificity Protein 1 (SP1) transcription factor is 
elevated in a variety of cancers including glioma, pancreatic, lung, breast, gastric and 
thyroid cancer and is directly O-GlcNAc modified [79]. This modification stabilizes SP1 
protein in the context of diabetes and increases in transcriptional activity in both diabetes, 
hyperglycemia in retinal cells and lymphoma [80-82]. While it has become evident that 
OGT and O-GlcNAc play critical roles in cancer metabolism and survival, it remains 
unclear how OGT is elevated in cancer cells. 
 
 
 
 
 
1.3 Figures and Figure Legends 
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Figure 1: Hexosamine Biosynthetic Pathway The hexosamine biosynthetic pathway 
diverges from glycolysis at fructose-6-phosphate and combines metabolic intermediates 
from amino acid, fatty acid and nucleotide metabolism to generate the amino-sugar UDP-
GlcNAc. The rate limiting enzyme in this pathway is GFAT.  
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Figure 2: O-GlcNAcylation 
Diagram depicting the dynamic and reversible O-GlcNAc modification in which N-
Acetylglucosamine is attached to serine and threonine residues of target proteins via O-
GlcNAc Transferase (OGT) and removed by O-GlcNAcase (OGA)  
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Figure 3: O-GlcNAc Transferase 
Full length human OGT contains 13 tetracopeptide repeat domains (TPR) which facilitate 
interaction with other proteins, and two catalytic domains (CDI and CDII) separated by a 
nuclear localization domain (NLS). Adjacent to the CDII at the C-terminus, OGT protein 
has a PPO domain responsible for binding phosphoinositide species.  
 
 
                          
Figure 4: O-GlcNAcylation and OGT levels in disease 
OGT/O-GlcNAcylation is elevated in a wide variety of cancers as well as diabetes. This 
modification is globally decreased in Alzheimer’s disease which corresponds to an 
increase in OGA and a decrease in OGT.  
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Figure 5: OGT relevance in normal biology and disease 
OGT directly O-GlcNAc modifies many known proteins in normal biology acting to 
regulate stemness, circadian rhythm, protein degradation and synthesis and epigenetics. 
Many of these proteins are deregulated and have altered levels of O-GlcNAc 
modification which directly contributes to or correlates with disease states including 
cancer, diabetes and Alzheimer’s disease 
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Table 1: OGT/O-GlcNAc and OGA status in different cancer types 
OGT (transcript or protein) and/or O-GlcNAc are elevated in all cancers listed. OGA 
levels were determined to be decreased in or correlate with survival in several cancers 
examined. Citations provided for work summarized in table.  
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CHAPTER 2: BREAST CANCER OVERVIEW AND CANCER METABOLISM 
2.1 Breast Cancer Overview 
2.1.1 Breast Cancer Subtypes 
Breast cancer is a heterogeneous disease developing as a consequence of genetic 
mutation influenced by a variety of factors. Globally, deaths attributed to this disease are 
estimated at 450,000 annually [83]. Looking more specifically at the United States, it is 
estimated that 1 in 8 women will develop breast cancer in their lifetime and it is the 
second most lethal cancer in U.S. females [84]. Despite increased ability of detection and 
treatment, insight into biological heterogeneity remains incomplete. Stratification and 
classification by molecular markers has greatly improved treatment guidelines and our 
understanding of prognosis and risk factors. Extensive characterization of genetic profiles 
of breast cancer (DNA or mRNA instead of histology) has resulted in classification into 4 
main subtypes of breast cancer [83, 85].  These subtypes consist of luminal A, luminal B, 
HER2-enriched and Basal-like. Molecular markers related to both luminal A and B 
subtypes are involved in proliferation and cell cycle as well as hormonal/luminal 
signaling [83]. Luminal breast cancers represent the majority of hormone receptor (HR)+/ 
HER2- cancers. When comparing luminal A and B, luminal B has higher expression of 
proliferative markers and less expression of luminal markers like progesterone receptor 
(PR). HER2-enriched subtype cancers have high expression of the receptor tyrosine 
kinase ErbB2/HER2, moderate expression of luminal genes and very low expression of 
basal-like genes. This subtype has the most genomic mutations and a high percentage of 
P53 mutation (72%) [83]. Basal-like breast cancers have the highest P53 mutations 
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(80%), high expression of keratins normally found expressed in the basal epithelium and 
moderate to low expression of HER2 and luminal markers. Basal-disease is also 
associated with BRCA mutations and aggressive clinical presentation [83]. Historically 
triple-negative (TN) and basal-like have been used interchangeably and most TN breast 
cancers (thought of as ER-,PR-,HER2-) qualify as basal-like (86%). When Prat et. Al 
examined almost 900 TN tumors, 86.1%, 9.1%, 3.2% and 1.6% were identified as basal-
like, HER2+, luminal B and luminal A respectively highlighting that characterization is 
strong however imperfect when pathology and molecular markers are taken into account 
[83].  
2.1.2 Breast Cancer Development  
The hallmarks of cancer not only outline the biological changes required to define a 
malignant cell but also put forth a model by which progressive evolution from a normal 
cell to a malignant cell occurs. This model dictates that genetic instability (combinations 
of epigenetic and genetic changes) which is also considered a hallmark of cancer, occur 
over time generating the genetic diversity that result in behavioral differences allowing 
for the ability of cells to escape confinements of normal cells and proliferate rapidly. 
Through alterations in signaling driven by genomic modifications, cancer cells  also meet 
each category/hallmark, including things such as; immune and apoptotic avoidance, 
sustained proliferation and angiogenesis, altered metabolic regulation and invasion and 
metastasis [86]. Breast cancer exists as a wildly heterogeneous disease exhibiting both 
inter- and intra-tumoral diversity. This variety stems from the range of cell types which 
comprise breast tumors as well as the differences in genetics within cells. Broad 
groupings based on molecular expression (outlined above) has aided in classifying patient 
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tumors into subtypes, dictating treatment strategy and predicting tumor progression and 
outcome. Development of breast cancer, regardless of subtype, is initiated and driven by 
genetic changes attained as well as influence from tumor microenvironment. Family 
history is one of the strongest determinants of risk, along with the well-documented risk 
factor – age [87]. Well known DNA repair genes (namely BRCA1, BRCA2 and TP53) 
can contain germline mutations accounting for excess risk of cancer development [88]. 
However, the excess risk added by the occupancy of these high-penetrance mutations is 
low leading researchers to believe that moderate and low-penetrance heritable mutations 
may account for other cases [88]. Pathological breast cancer initiation and progression 
involves ductal hyperproliferation, ductal carcinoma in situ (DCIS), and finally malignant 
invasive disease [88]. The evolution from accelerated proliferation and escape from 
growth restraints to metastasis requires that cells degrade the physical barrier of the 
basement membrane, leave the primary site via vasculature, survive in circulation and 
then seed and proliferate at metastatic sites (Figure 7) [88]. Cancer development and 
progression are influenced by the microenvironment which consists of cells both 
surrounding and integrated into the tumor. These include endothelial cells, cancer-
associated fibroblasts, inflammatory immune cells, bone marrow-derived stromal cells 
and cancer stem cells [86]. It was previously hypothesized that mutation occurred in a 
preferred order, whereby each new mutational step led to clonal expansion of cells 
containing that mutation increasing the probability of multiple mutations occurring within 
the same cell [89].  Stepwise mutational changes resulting in the development of cancer 
are clear in particular cancer types such as colorectal however do not account for the vast 
molecular subtypes found in other cancers like breast cancer. Breast cancer may require 
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much more complex models to explain neoplastic changes and heterogeneity [83, 89]. 
Both epidemiological and human tumor analysis suggest that breast cancer arises from 
two distinct mammary cell types resulting in basal-type and non-basal subtypes [83].  
Incredible changes in both genetic and epigenetics within cells contribute to the 
development of breast cancer. Somatic mutations, altered protein and miRNA 
(microRNA) expression, copy number changes and acetylation and methylation 
deregulation all contribute to the pathogenesis of cancer and the development of cancer 
progenitor cells [84]. When examining somatic mutation in coding exons within 100 
tumors, Stephens et. Al. found nearly 7,500 somatic point mutations in 21,416 genes that 
code for protein. While individual tumors mutation numbers were very diverse, many 
mutations occurred in genes classified as oncogenes or tumor suppressors such as 
BRCA1, TP53, AKT1, PTEN, RB1, KRAS and PI3KCA. Somatic mutations were found 
in 10% of all breast cancers in PI3KCA, TP53 and GATA3 in analysis by the Cancer 
Genome Atlas. Interestingly, within molecular subtype, mutation number as well as type 
differed. One example of this is TP53 mutations which generally contained missense 
mutations in luminal A and B subtypes but often contained frameshift and nonsense 
mutations in basal-like breast cancer [85].  
2.1.3 Breast Cancer Treatment 
Receptor status/molecular subtype of breast cancer aids in predictive response to 
particular therapies and is used to dictate therapy. In the case of suspected metastasis, 
biopsies are performed to confirm the presence of secondary tumors and molecular 
subtype [90]. Metastatic disease outcome has been improved through treatment with 
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targeted therapies against HER2 in HER2-enriched breast cancer and endocrine therapies 
in ER+ and PR+ breast cancers. Metastatic disease that is ER+, PR+ and even HER2+ 
will eventually develop resistance to endocrine and HER2 targeted therapies requiring 
cytotoxic chemotherapy [90]. Currently there are not effective targeted therapies 
available for the treatment of TN breast cancer, which is quite aggressive [91]. Metastatic 
disease will eventually exhaust available chemotherapeutic options which is why is it 
incurable [90]. Treatment failure and recurrence or persistence of disease can result from 
intrinsic resistance to standard therapies that exists in cells prior to treatment or resistance 
that is developed through acquired mechanisms resulting from treatment [92]. 
Mechanisms to overcome resistance are being explored in all subtypes of breast cancer. A 
persistent risk of recurrence exists even in early stage ER+ breast cancer patients which is 
only modestly reduced by extending treatment periods for endocrine therapy [90, 93]. 
The dormancy of tumor cells within the system is thought to be responsible for 
recurrence in patients who experience long periods between initial treatment and 
development of relapse [90]. Some have determined that metastatic ER+ breast cancers 
have either mutant ER, or deregulated downstream factors such as PI3K/AKT or mTOR. 
A strategy for overcoming developed resistance and recurrence could be targeting these 
other factors [90]. A second strategy to combat resistance to endocrine therapy is to 
downregulate ER using agents such as fulvestrant in combination with endocrine therapy. 
Benefits to combinations depended on prior patient treatment as well as dosing and 
addition of other therapies [90]. Impressive pre-clinical and phase 2 results in 
combination treatment with cell-cycle kinase inhibitor palbociclib and tamoxifen or 
letrozole (both hormone therapies) led to approval of these combinations for treatment of 
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some metastatic ER+ breast cancers [90]. The standard of care in the treatment of HER2+ 
breast cancer is the use of targeted therapies such as lapatinib, pertuzumab, and 
trastuzumab emtansine [90]. Many mechanisms of resistance have been found to these 
targeted agents including several that activate downstream pathways despite blocking 
HER2 or receptors with which HER2 binds to activate signaling. These downstream 
pathways consist of PI3K (also responsible for resistance in ER+ breast cancer as 
mentioned above), ERK signaling pathway, and mTOR [94]. Mutations in HER2 itself or 
loss of HER expression can also account for resistance to HER2-targeting agents [95, 
96]. Targeting these downstream effectors, as mechanisms of resistance involving them 
are revealed, is currently underway with testing the addition of mTOR inhibitors and 
MEK inhibitors to HER2 targeted therapies [94, 97].  Targeted agents are needed for the 
treatment of TN breast cancer as current strategies employed to treat this subtype of 
breast cancer are limited to more general chemotherapeutic agents. Platinum treatment 
has emerged as a beneficial treatment agent in some patients as well as the use of 
poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors specifically in BRCA 
mutant patients [90]. The expansion of clinical trials to include the use of new agents, as 
more mechanisms of resistance are unveiled have and will undoubtedly lead to better 
outcomes in patients through revision of treatment options available. This is precisely 
why persistence in expanding our knowledge of signaling pathways that regulate cancer 
cell growth and survival and their interplay with current targets for therapy, along with 
identification of novel targets in different types of breast cancer are required and 
important.  
2.2 Cancer Cell Metabolism 
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2.2.1The Warburg Effect  
Cancer cells exhibit altered metabolism characterized by increased glucose and glutamine 
uptake to promote glycolysis in the presence of normal oxygen conditions [50, 98]. This 
modified metabolic state, known as the Warburg effect, allows cancer cells to acquire a 
large allotment of nutrients from their environment, a phenomenon that is widely used in 
vivo to monitor tumor growth using 2FDG-PET imaging [50, 98]. Although this use of 
nutrients is inefficient in terms of the amounts of ATP produced, a sizeable amounts of 
carbon and nitrogen in the form of lactate and ammonia are secreted from cancer cells 
into the extracellular environment. These excreted nutrients can then be taken in by 
neighboring tumor cells for use as fuel. Aerobic glycolysis maintains an adequate amount 
of carbon backbones for macromolecular synthesis in the form of acetyl-CoA, NADPH 
and amino acids important in providing the biomass required for cancer cell growth and 
proliferation in conjunction with maintaining a redox balance by means of production of 
large amounts of NADPH [98, 99].  
2.2.2 Drivers of altered metabolism 
 It is now understood that this metabolic phenomenon first reported by Otto 
Warburg [100], is generated largely through oncogenic activation of signal transduction 
pathways and transcription factors as well as loss of tumor suppressors [101-104]. The 
phosphatidylinositol-3-kinase (PI3K)/Protein kinase B (or AKT)/mechanistic target of 
rapamycin (mTOR) is an important pathway (Figure 6) that lies downstream of receptor 
tyrosine kinase (RTK) activation and is known to be deregulated in a wide majority of 
cancer types [101, 104, 105]. Ligand binding to RTKs upstream activates PI3K which in 
turn results in phosphorylation of phosphoinositol lipids at the plasma membrane. This 
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activation then recruits and triggers AKT. PI3K activity is under regulation by the tumor 
suppressor phosphatase and tensin homolog (PTEN), however many transformed cells 
contain inactivating mutations in PTEN [104]. The PI3K/AKT pathway directly 
contributes to altered metabolism of cancer cells by inducing cells to take up excess 
glucose via regulation of glucose transporters [50, 102] and via activation of the 
mechanistic target of rapamycin complex 1 (mTOR1) signaling pathway [106]. In 
response to changes in energy status, regulation of cell growth by AKT is mediated 
through downstream phosphorylation and inhibition of tuberos sclerosis complex 1/2 
(TSC1/2), a factor which acts to inhibit mTORC1. The mTOR pathway senses the energy 
status of a cell in response to a number of environmental cues and in turn alters cell 
growth and metabolism. One factor in energy status is amino acid availability which 
activates mTORC1-dependent translation factors 4E-binding protein 1 (4E-BP1) and p70 
S6 kinase 1 (S6K1) to enhance protein synthesis of main transcription factors that control 
metabolism such as c-MYC, sterol regulatory element binding protein 1 (SREBP-1), and 
hypoxia inducible factor 1-alpha (HIF-1α) [101]. c-MYC and SREBP-1 relation to 
OGT/O-GlcNAcylation will be discussed in depth later in this thesis.  
 The oncogenic transcription factor c-MYC is overexpressed in many cancer types. 
Despite its prevalence for deregulation it is very infrequently mutated in coding sequence 
[107]. c-Myc is elevated at the protein level through amplification, chromosomal 
translocation and post-translational modification including phosphorylation [107].  
Binding to DNA and transcriptional activity requires binding to its obligatory partner 
MAX as it functions as a heterodimer in combination with this protein [107]. c-Myc 
promotes glutamine uptake and utilization via transcription of several of its targets 
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(Figure 6) [108]. This yields nitrogen required to synthesize nucleotides and amino acids 
[98]. In addition, glutamate production dependent on c-MYC, acts to feed the TCA cycle 
whose intermediates react to increase NADPH production, thus maintaining the redox 
balance in cancer cells [98, 109]. The oncogene c-MYC is involved in the regulation of 
cell cycle progression, cell growth, glucose uptake and glycolysis and is commonly 
amplified in breast cancer [110]. Moreover, MYC overexpression is associated with 
highly aggressive clinical features correlating with poor patient outcome [111]. 
As mentioned above SREBP-1 functions as a transcription factor downstream of 
mTORC1. SREBP-1 acts to induce expression of genes involved in de novo fatty acid 
biosynthesis providing membrane components for the generation of new cells [101]. High 
SREBP-1 expression is associated with poor prognosis in a number of cancer types, and 
has been shown to sustain cancer cell growth and survival through lipogenic functions 
[112, 113].  
 In the progress of cancer growth, rapid cellular proliferation removes tumors from 
proper proximity to the blood supply generating low oxygen tension, or hypoxia [114, 
115]. When exposed to these conditions, hypoxia inducible factor  (HIF-1αβ) functions to 
promote cell survival through induction of transcriptional targets including glucose 
transporters and glycolytic genes as well as angiogenic factors to promote restoration of 
oxygen concentration [115].  HIF-1 transcription factor consists of HIF-1α which is 
stabilized in the absence of oxygen, and a constitutively expressed binding partner HIF-
1β which bind together at hypoxic regulatory elements in promoters of target genes [115]. 
Prolyl hydroxylation occurs at two proline residues on HIF-1α, when oxygen is ample, 
allowing for ubiquitination and recognition of HIF-1α by its E3 Ubiquitin ligase von 
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hippel lindau protein (pVHL) [115]. This precedes HIF-1α ubiquitination and 
proteasomal degradation, which is perturbed in hypoxic environments. Some renal 
cancers contain germline loss-of-function mutations in VHL [115]. Low oxygen 
concentration is associated with increased metastasis and decreased survival in breast and 
ovarian cancer patients and can result from resistance to radiation and chemotherapy 
[115, 116]. Several mechanisms exist in which HIF-1α protein expression may be 
increased independent of oxygen concentration [115]. 
 Another important pathway downstream of activated RTKs is the 
RAS/RAF/MAPK pathway (Figure 8). This functions to regulate both normal cell growth 
and malignant transformation [104]. Glucose uptake and utilization to feed anaerobic 
glycolysis and the uptake of lysophospholipids contributing to lipid pools and energy are 
driven by mutations in oncogenic Ras in some cancers [104, 117, 118].  
 Metabolism and energy homeostasis are controlled at least partly through the liver 
kinase B1 (LKB1)/AMP-activated protein kinase (AMPK) signaling axis [119, 120]. 
AMPK acts through sensing and responding to changes in the cellular AMP to ATP ratio 
as it functions to block growth pathways that consume metabolic precursors and cost 
energy [119-121]. A major task for AMPK is inhibiting mTORC1 through 
phosphorylation of the TSC1/2 complex and mTORC1 complex protein RAPTOR which 
blocks the kinase activity of mTOR [119, 122]. Loss of tumor suppressor LKB1, which 
acts upstream of AMPK, in somatic cells is associated with the progression in a variety of 
cancers (Figure 8) [119].  This nutrient sensor and mitogenic restraint is a crucial factor 
in cancer development, progression and survival and is viewed as a potential area where 
therapeutics may be developed [123].   
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2.3 Figures and Figure Legends 
 
 
Figure 6: Warburg Effect: Metabolism in Cancer  
Diagram of metabolism in cancer cells. The rate of glucose uptake in cancer is achieved 
through upregulation of glucose transporters through oncogenic signaling. This glucose is 
utilized through glycolysis (driven by oncogenes and inhibited by tumor suppressors that 
are often downregulated) to produce more lactate that is secreted from the cell. Glycolytic 
intermediates are diverted through the pentose phosphate pathway (PPP) to support 
nucleotide synthesis. Glutamine uptake is also upregulated by oncogenes feeds to the 
TCA cycle which also utilizes pyruvate. Lipid synthesis is supported by citrate derived 
acetyl-CoA as amino acid synthesis is supported by citrate derived oxaloacetate (OAA). 
G6P (Glucose-6-Phosphate), F6P (Fructose-6-Phosphate), PEP (Phosphoenolpyruvic 
acid), R5P (Ribose-5-Phosphate), αKG (alpha-Ketoglutarate).  
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Figure 7: Model of breast cancer progression  
Normal breast cells are contained by a basement membrane and organized, polarized 
layers of luminal epithelial and myoepithelial cells. Through genetic and epigenetic 
alterations, normal cells become hyperproliferative.  Influences from the 
microenvironment come from different cell types including fibroblasts and endothelial 
cells. Transitions from an in situ state to invasive status required degradation of the 
basement membrane and escape from containment as well as survival through the travel 
to a metastatic site where cancer cells seed and proliferate.  
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Figure 8: Major Signaling pathways in cancer Receptor Tyrosine Kinases (RTKs) can 
activate downstream signaling to promote cancer cell growth and survival, angiogenesis, 
cell cycle and promote the Warburg Effect. Downstream pathways such as the 
Ras/Raf/MEK/ERK and PI3K/AKT mTOR are required for these processes through 
upregulation of specific transcription factors. These can be upregulated through 
amplification and upregulation of oncogenes and loss of tumor suppressors.  
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CHAPTER 3: PI3K/MTOR/MYC AXIS REGULATES OGT EXPRESSION IN 
BREAST CANCER 
3.1 Introduction:  
Here, we show that the master nutrient signaling PI3K/AKT/mTOR pathway is 
required for elevation of OGT and O-GlcNAcylation in breast cancer cells. We also 
demonstrate that hyperactivation of AKT or mTOR is sufficient to elevate OGT protein 
and O-GlcNAcylation levels. Downstream of mTOR activation, we observe that c-MYC 
is required and sufficient to drive OGT protein elevation and increase O-GlcNAcylation 
in cancer cells via c-MYC regulation of HSP90A. Importantly, we show that Myc-driven 
cancer cells elevate OGT and O-GlcNAcylation and require OGT activity for cancer cell 
survival. Our data is the first to link mTOR/MYC activity to increased OGT/O-
GlcNAcylation that contributes to the oncogenic phenotype seen in multiple cancers.  
3.2 Results 
3.2.1 O-GlcNAcylation and OGT levels require PI3K and mTOR activation in 
cancer cells 
We have previously demonstrated that breast cancer cells contain elevated OGT and O-
GlcNAcylation levels compared to normal mammary epithelial cells [59]. In addition, 
stable overexpression of the active form of the receptor tyrosine kinase ErbB2/HER2 in 
non-transformed mammary epithelial MCF-10A cells resulted in elevated OGT and O-
GlcNAc levels [59]. Since ErbB2 activation stimulates numerous signaling cascades 
including PI3K/AKT, Ras/MEK/ERK and mTOR [111], we examined which signaling 
pathway was responsible for increased OGT and O-GlcNAc levels in breast cancer cells 
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(Figure 9). We aimed, through these studies, to determine how OGT protein was 
regulated in breast cancer since little was known of its regulation in either cancer or 
normal cells. We had previously found that mRNA of OGT was not significantly 
increased in any breast cancer subtypes examined compared to normal samples which 
leaves a question as to how OGT protein is elevated in breast cancer [21]. We tested a 
panel of breast cancer cells that represent different subtypes including: estrogen receptor 
positive (MCF-7 cells), ErbB2/HER2 positive (SKBR-3 cells), and triple negative/basal 
breast cancers (MDA-MB-231 and SUM-159 cells) [124]. We expected that inhibition of 
one or several pathways/axes would result in reduced OGT protein expression providing 
us with insight into what lay upstream of OGT. Cells were treated with vehicle control 
(DMSO) or pharmacological inhibitors against the PI3K, mTOR and MEK signaling 
pathways (Figure 9). Treatment of all breast cancer cells with PI3K (LY294002) and 
mTOR inhibitor (Rapamycin) reduced O-GlcNAc levels compared to control and 
decreased OGT protein levels (Figure 10-11). Treatment of breast cancer cells with PI3K 
inhibitor (LY294002) significantly reduced OGT levels in MDA-MB-231, SKBR-3, 
MCF-7 but not SUM-159 cells. Inhibition of MEK (U0126) had negligible effects on 
OGT levels and O-GlcNAcylation (Figure 10-11). These data suggest that the PI3K 
/mTOR pathway is a key regulator of OGT and O-GlcNAc levels in multiple breast 
cancer cell lines with different genetic origins. To determine if the PI3K/mTOR pathway 
regulates OGT at the level of RNA, quantitative real-time PCR (qRT-PCR) was 
performed. Treatment of breast cancer cells MDA-MB-231, MCF-7, SKBR-3 and SUM-
159 (Figure 10-11) with inhibitors of PI3K, mTOR or MEK pathways did not 
significantly reduce OGT RNA levels suggesting that PI3K/mTOR-mediated regulation 
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of OGT protein levels is RNA-independent. Interestingly, protein levels of OGA were not 
elevated in breast cancer cells treated with PI3K or mTOR inhibitors (Figure 12) 
suggesting that the decrease in O-GlcNAcylation caused by inhibitors of PI3K/mTOR 
pathway is primarily a result of diminished OGT protein levels. Thus, OGT protein and 
global cellular O-GlcNAcylation levels are maintained in breast cancer cells via PI3K 
and mTOR activation independent of OGT mRNA regulation. 
3.2.2 AKT or mTOR activation is sufficient to elevate OGT protein expression and 
O-GlcNAcylation 
Since cancer cells require PI3K and mTOR activation to maintain OGT and O-
GlcNAc levels, we examined whether these pathways were sufficient to increase OGT 
and O-GlcNAcylation levels. PI3K can activate many pathways including the kinase 
AKT (Protein Kinase B) [125]. To determine whether AKT activation alone was 
sufficient to increase OGT and O-GlcNAc levels in epithelial cells, we stably 
overexpressed an active form of AKT1 (Myr-AKT1) in the normal mammary epithelial 
cell line MCF-10A. Cells stably expressing Myr-AKT contained increased 
phosphorylated AKT and activated mTOR pathway as measured by phosphorylation of 
p70 S6 kinase (S6K) (T389) as well as elevated OGT protein levels and increased overall 
protein O-GlcNAcylation compared to control cells (Figure 13A). Consistent with the 
MEK-inhibitor results, MCF-10A cells overexpressing a constitutively active form of 
MEK2 (MEK2-DD) did not alter OGT and protein O-GlcNAcylation levels (Figure 
15A). This result is notable since MCF-10A-MEK2-DD cells have a pronounced 
phenotype when cultured in a three-dimensional (3D) culture system (Figure 15B) that 
allows bypass of growth suppression and anoikis resistance [126]. This result 
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demonstrated that OGT and O-GlcNAcylation levels are not elevated simply as a result 
of hyperproliferation which is important in concluding that OGT protein is specifically 
regulated by the PI3K/AKT pathway. We conclude that activation of the AKT pathway, 
but not MEK/ERK pathway, is sufficient to elevate OGT and O-GlcNAcylation levels in 
human breast epithelial cells.   
To test whether mTOR activation is also sufficient to increase levels of OGT and 
O-GlcNAcylation, we examined OGT/O-GlcNAc levels in mouse embryo fibroblasts 
(MEFs) containing deletion of TSC2. As mentioned previously, TSC1 and TSC2 are 
components of a complex that negatively regulates mTORC1 nutrient signaling and 
interestingly, inactivation of either TSC1 or TSC2 results in elevated mTOR activity, is 
associated with uncontrolled cell growth and division and is linked to benign tumor 
growth [106]. To determine if mTOR activation was sufficient to increase OGT and O-
GlcNAc levels, wild-type and TSC2 deficient MEFs were analyzed. As expected, basal 
phosphorylation levels of mTOR targets p70 S6K (T389) and 4EBP1 (T70) were elevated 
in the TSC2 null cells compared to wildtype MEFs (Figure 13B) verifying constitutive 
mTOR activation. Interestingly, TSC2 null cells showed elevated OGT and O-GlcNAc 
levels (Figure 13B-C) further implicating the mTOR pathway in the regulation of O-
GlcNAc cycling. However, TSC2 null cells also displayed significantly lower OGA 
levels (Figure 14B) suggesting that increased O-GlcNAcylation in these cells may be due 
to both elevation of OGT and reduction of OGA. To determine if OGT and O-GlcNAc 
levels were directly controlled by deregulated mTOR activity in these cells, TSC2 null 
MEFs were treated with Rapamycin. Similar to the cancer cells, inhibition of mTOR in 
TSC2 null MEFs resulted in a decrease in OGT and O-GlcNAcylation (Figure 14A). 
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These results reveal that, in addition to AKT, activation of mTOR is also sufficient to 
increase OGT protein levels and increase O-GlcNAcylation.  
3.2.3 c-MYC regulates O-GlcNAcylation and OGT protein expression in cancer 
cells. 
Many pathways are altered by activation of mTOR [106]. Since OGT is required 
for metabolic pathways in cancer cells [76], we hypothesized that pathways downstream 
of mTOR associated with metabolic regulation may be involved in OGT/O-GlcNAc 
regulation. Since c-MYC is a key metabolic transcription factor downstream from the 
mTOR pathway [127], we examined whether this transcription factor is involved in OGT 
and O-GlcNAc regulation in cancer cells. c-MYC is amplified in multiple cancers, plays 
a significant role in cancer cell proliferation, growth and apoptosis and has been strongly 
implicated in regulating cancer metabolism [110]. To verify that c-MYC expression is 
downstream of mTOR in breast cancer cells, we examined c-MYC levels in breast cancer 
cells after treatment with Rapamycin or LY294002. Inhibition of PI3K and mTOR, but 
not MEK, significantly reduced c-MYC expression in MDA-MB-231, SKBR-3, MCF-7 
and SUM-159 breast cancer cells and correlated with reduced OGT protein levels in these 
cells (Figure 10A, 11A, 12C). To test whether c-MYC was required for OGT expression 
in breast cancer cells, we targeted c-MYC with two different lentiviral shRNA constructs 
and determined that decreasing MYC expression in MDA-MB-231 significantly reduced 
OGT levels and O-GlcNAcylation compared to cell containing control shRNA (Figure 
16A-B). Consistent with our data regarding OGT expression under conditions of 
inhibition of PI3K and mTOR, there was no significant difference in OGT mRNA in cells 
expressing c-MYC RNAi as compared to control cells (Figure 18A). Thus, both 
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PI3K/mTOR and c-MYC regulate OGT protein levels independently of mRNA. To 
determine if c-MYC expression is sufficient to regulate OGT expression, we 
overexpressed c-MYC in MCF-10A cells. Cells overexpressing c-MYC displayed 
increased expression of its transcriptional target cyclin D1 (Figure 17A) and significantly 
upregulated OGT protein levels and O-GlcNAcylation compared to control cells (Figure 
17A-B). The increase in OGT protein levels in MYC-overexpressing MCF-10A cells was 
also independent of changes in OGT mRNA levels (Figure 18B). Thus, downstream from 
mTOR, c-MYC is required and sufficient to regulate OGT protein levels and O-GlcNAc 
cycling in an RNA-independent fashion. 
3.2.4 c-MYC regulation of HSP90A is required for OGT expression in cancer cells 
Recent studies have shown that the chaperone HSP90A can bind OGT and regulate its 
proteasomal degradation in endothelial cells [40]. Interestingly, HSP90A is a c-MYC 
transcriptional target and contributes to c-MYC-induced transformation [128], thus we 
examined the potential connection between c-MYC, HSP90A and proteasomal 
degradation of OGT in cancer cells. To test whether reducing c-MYC levels in cancer 
cells led to reduction of OGT protein via the proteasome, we treated MDA-MB-231 cells 
containing c-MYC RNAi with the proteasome inhibitor lactacystin. Cells treated with 
lactacystin reversed MYC-RNAi induced reduction of OGT protein compared to control 
treated cells (Figure 19A) demonstrating that MYCs control of OGT requires the 
proteasome. Consistent with the idea that mTOR regulation of Myc can control OGT via 
proteasomal degradation, we found that the decrease in OGT protein levels observed with 
Rapamycin treatment was also reversed following lactacystin treatment (Figure 20A). 
Thus, mTOR and c-MYC regulation of OGT protein levels is proteasomal-dependent. 
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 Consistent with previous findings that c-MYC regulates HSP90A, MDA-MB-231 
cells stably expressing c-MYC shRNA contained significant decreases in HSP90A 
protein levels (Figure21A) and RNA levels (Supplemental Figure 21B) compared to 
control RNAi cells. Conversely, MCF-10A cells overexpressing c-MYC contained 
increased levels of HSP90 compared to control cells (Figure 17A). To determine whether 
OGT interacts with HSP90 in breast cancer cells, we immunoprecipitated either OGT or 
HSP90 and examined interaction between these two proteins. Immunoprecipitating either 
OGT (Figure 22A) or HSP90 (Figure 22B) from MDA-MB-231 cell lysates showed that 
endogenous OGT and HSP90 interact in breast cancer cells.  To test whether HSP90A 
activity in cancer cells is associated with OGT and O-GlcNAc cycling, we treated MDA-
MB-231 cells with HSP90 specific inhibitor 17-Demethoxy-17-allyaminogeldanmycin 
(17-AAG) [129]. Inhibition of HSP90 increases ubiquitination and proteasome-dependent 
degradation of client proteins [130]. Consistent with the idea that OGT is an HSP90A 
client protein, MDA-MB-231 cells treated with 17-AAG displayed decreased OGT and 
O-GlcNAcylation levels compared to control cells (Figure 23A). This decrease in OGT 
expression was independent of changes in Myc levels and was partially reversed when 
cells were also treated with lactacystin to block proteasomal degradation (Figure 20A). 
To test directly whether HSP90A is required for OGT expression in cancer cells, we 
reduced HSP90A expression in breast cancer cells using two different RNAi constructs. 
Reducing HSP90A levels in MDA-MB-231 cells resulted in significant decreases in OGT 
protein levels and reduced O-GlcNAcylation (Figure 24A-B). Conversely, 
overexpressing HSP90 in HEK-293T cells increased both OGT levels and elevated O-
GlcNAcylation (Figure 23B). In addition, MCF-10A-MYC overexpressing cells contain 
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increased HSP90A expression and increased OGT and O-GlcNAcylation as mentioned 
above, (Figure 25A-B) suggesting increased association between OGT and HSP90A in a 
MYC-dependent manner. Reducing HSP90A levels via RNAi in MYC-overexpressing 
cells resulted in significant inhibition of OGT protein levels and reduced total O-
GlcNAcylation (Figure 25A-B). Together these results show that MYC regulation of 
HSP90A controls OGT protein levels and O-GlcNAcylation in cancer cells.  
3.2.5 Myc-driven tumor cells contain elevated OGT and O-GlcNAc levels and 
require OGT for survival. 
Overexpression of c-Myc under the control of mouse mammary tumor virus 
(MMTV) results in the development of mammary tumors [131]. To determine if c-MYC 
driven tumors show elevated OGT and O-GlcNAcylation, we compared COMMA-1D 
cells, isolated from a mid-pregnant Balb/C mouse, to mammary tumor epithelial cells 
(MTECs) isolated from MMTV-MYC transgenic mice. The MTEC-MYC cells displayed 
elevated c-MYC levels as well as an increase in both OGT protein and O-GlcNAcylation 
(data not shown). To examine whether MYC-driven tumors have altered OGT and O-
GlcNAcylation in vivo, we compared the levels of OGT and O-GlcNAc from mammary 
tissues harvested over the course of tumor progression from nulliparous female MMTV-
MYC transgenic mice. O-GlcNAcylation was elevated in MYC-driven hyperplasic 
lesions compared with normal mammary glands of Myc+ females, and was further 
increased in late stage carcinomas relative to the hyperplasias (Figure 26A). Tumor tissue 
also displayed significantly upregulated OGT expression compared to normal mammary 
glands (Figure 26B).  
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MYC-driven cancers are known to be highly proliferative but also have high 
levels of apoptosis [110]. We examined whether targeting OGT using a chemical 
inhibitor could sensitize these cells to apoptosis compared to non-tumorigenic mammary 
epithelial cells. Treatment of MTEC-MYC cells or MCF-10A cells with OGT inhibitor 
Ac-5SGlcNAc reduced total levels of O-GlcNAcylation (Figure 27A, 28A). However, 
Ac-5SGlcNAc treatment increased caspase-3 cleavage (Figure 27A) and significantly 
reduced cell viability as measured by crystal violet staining (Figure 28B, 29A) solely in 
the MTEC-MYC cells as apoptotic markers and cell viability was not altered in MCF-
10A cells upon treatment. Since we have recently shown that reducing OGT in cancer 
cells leads to ER stress and apoptosis in a CHOP-dependent manner [76] we examined 
whether inhibiting OGT in MYC-driven cancer cells also activated ER stress. Indeed, 
treating MTEC-MYC cells with OGT inhibitor Ac-5SGlcNAc induced phosphorylation 
-2 BH3-only pro-apoptotic 
protein Bim (Figure 27A). Importantly, treating MCF-10A cells with this inhibitor did 
not activate ER stress or induce expression of these markers (Figure 27A).  This selective 
cell death of MYC-driven cancer cells was also observed in 3D culture as MTEC-MYC 
cells treated with the OGT inhibitor contained elevated cleaved caspase-3 staining 
compared to MCF-10A cells (Figure 29B).  Thus, Myc-driven breast cancer cells increase 
OGT and O-GlcNAcylation and inhibition of O-GlcNAcylation in these cells induces ER 
stress and apoptosis. 
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3.3 Figures and Figure Legends 
 
Figure 9: RTK/PI3K/mTOR pathway altered in majority of cancers Receptor 
Tyrosine Kinases (RTKs) can activate downstream signaling to promote cancer cell 
growth and survival. Downstream pathways such as the Ras/Raf/MEK/ERK and 
PI3K/AKT mTOR are important in many cancers and are upregulated through oncogenes 
and loss of tumor suppressors. In the subsequent studies shown here, inhibitors are used 
to decipher signaling. Inhibitors LY204992 (PI3K targeting), U0126 (MEK targeting, and 
Rapamycin (mTOR targeting) are used in these studies.  
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Figure 10: mTOR and PI3K are required for OGT protein expression 
(A) Western blot analysis of MDA-MB-231 and SKBR3 cells treated with inhibitors 
Rapamycin (Rap), LY294002 (LY) , U0126 or vehicle control (DMSO) were analyzed 
using the indicated antibodies. (B-C) RNA was isolated from cells treated with the same 
conditions as (A) and analyzed via qRT-PCR for mRNA expression. Changes in mRNA 
not significant.  
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Figure 11: mTOR and PI3K are required for OGT protein expression 
(A) Western blot analysis of MCF-7 and SUM-159 cells treated with inhibitors 
Rapamycin (Rap), LY294002 (LY) , U0126 or vehicle control (DMSO) were analyzed 
using the indicated antibodies. (B-C) RNA was isolated from cells treated with the same 
conditions as (A) and analyzed via qRT-PCR for mRNA expression. Changes in mRNA 
not significant.  
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Figure 12: Changes in O-GlcNAcylation are independent of OGA expression and 
correlate with MYC expression in breast cancer cells treated with inhibitors to 
mTOR and PI3K  (A-B) Western blot analysis of MDA-MB-231, SKBR3, MCF-7 and 
SUM-159 cells treated with inhibitors Rapamycin (Rap), LY294002 (LY) , U0126 or 
vehicle control (DMSO) were analyzed using the indicated antibodies. (C) Quantification 
of western blot analysis in represented in Figures 5 & 6. Mean +/- SE *p<0.05.  
 
 
44 
 
                         
Figure 13: PI3K/Akt and mTOR are sufficient to elevate OGT expression,.(A-B) 
Western blot analysis of MCF10A cells containing control or Myr-Akt overexpression 
and WT and TSC2-/- MEFs were analyzed using the indicated antibodies. (C) 
Quantification of western blot analysis represented (B). Mean +/- SE *p<0.05.  
 
45 
 
 
 
Figure 14: mTOR signaling is required for OGT protein expression independent of 
changes in OGA (A) Western blot analysis of TSC2 -/- MEFs treated with vehicle 
control (DMSO) or Rapamycin analyzed using the indicated antibodies. (B) Western blot 
analysis of WT and TSC2-/- MEFs analyzed with the indicated antibodies. Quantification 
of western blot analysis. Mean +/- SE *p<0.05.  
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Figure 15: MEK/ERK pathway is not sufficient to regulate OGT and O-
GlcNAcylation levels. (A) Protein was collected from MCF-10A cells stably expressing 
Control (pBabe) or an active form of MEK2 (pBabe-MEK-2-DD), and analyzed using 
western blot analysis with indicated antibodies.  (B) MCF-10A-Control or MCF-10A-
MEK2-DD cells were placed in 3D culture. At day 10, cells were fixed and stained with 
the indicated antibody and Topro-3 (nuclear stain), then imaged using confocal 
microcopy.  
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Figure 16: MYC is required for OGT protein expression (A) MDA-MB-231 cells 
containing control, shMYC-1, or shMYC-2 plasmids were analyzed by western blot with 
the indicated antibodies. (B) Quantification of western blot analysis. Mean +/- SE 
*p<0.05. Statistical analysis performed for separate proteins examined comparing 
shMYC#1 and shMYC#2 samples to control.   
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Figure 17: MYC is sufficient for OGT protein expression (A) MCF10A- control and 
MCF10A-cMYC cells were analyzed by western blot with the indicated antibodies. (B) 
Quantification of western blot analysis. Mean +/- SE *p<0.05.  
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Figure 18: MYC is required and sufficient for OGT protein expression independent 
of OGT mRNA (A) mRNA was isolated from MDA-MB-231 cells containing control, 
shMYC-1, or shMYC-2 plasmids and analyzed by qRT-PCR. (B) mRNA was isolated 
from MCF10A-control and MCF10A-cMYC cells and analyzed by qRT-PCR. OGT 
mRNA was normalized to PPIA expression in each sample then to control. Mean +/- SE 
*p<0.05, changes were not significant.  
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Figure 19: MYC regulates OGT via proteasomal degradation and OGT expression 
is not dramatically altered by substrate availability (A) Western blot analysis of 
MDA-MB-231 cells containing control, shMYC-1 or shMYC-2 plasmids, treated with 
vehicle control (DMSO) or proteasomal inhibitor lactacystin. Quantification was 
determined using ImageJ. (B) Western blot of MDA-MB-231 cells treated with vehicle 
control (DMSO), Rapamycin or LY294002 +/- 15mM GlcNAc was analyzed with the 
indicated antibodies. OGT protein expression was quantified using ImageJ software and 
displayed below.  
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Figure 20: mTOR and HSP90 regulation of OGT is at least partly dependent on the 
proteasome (A) MDA-MB-231 cells treated with vehicle control (DMSO), Rapamycin, 
or 17-AAG and +/- Lactacystin were analyzed with the indicated antibodies. 
Quantification of OGT protein expression was performed using ImageJ and is displayed 
below and in (B. Mean +/- SE *p<0.05. 
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Figure 21: MYC inhibition decreases HSP90 protein and mRNA in MDA-MB-231 
cells (A) MDA-MB-231 cells containing control, shMYC-1, or shMYC-2 were analyzed 
via western blot and protein expression was quantified and normalized to control. (B) 
mRNA was isolated from MDA-MB-231 cells containing control, shMYC-1 or shMYC-
2 cells and analyzed by qRT-PCR. HSP90 mRNA was normalized to PPIA expression in 
each sample then to control. Mean +/- SE *p<0.05. Statistical analysis performed for 
separate proteins examined comparing shMYC#1 and shMYC#2 samples to control.   
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Figure 22: OGT and HSP90 interact in MDA-MB-231 cells (A-B) 
Immunoprecipitation of control IgG, OGT or HSP90 from MDA-MB-231 cells analyzed 
by western blot with the indicated antibodies Quantification displayed below. Mean 
changes were significant p<0.05. Immunoprecipitations normalized to expression in IgG 
control lanes.  
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Figure 23: HSP90 is required and sufficient for OGT expression (A) MDA-MB-231 
cells were treated with increasing doses of 17-AAG and analyzed by western blot using 
the indicated antibodies. (B) Western blot of HEK-293T cells transfected with control or 
HSP90 plasmids were analyzed with the indicated antibodies.   
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Figure 24: HSP90 is required for OGT expression (A) MDA-MB-231 cells containing 
control, shHSP90 -1 or shHSP90-2 plasmids were analyzed by western blot using the 
indicated antibodies. (B) Quantification of protein expression from conditions in (A). 
Mean +/- SE *p<0.05. Statistical analysis performed for separate proteins examined 
comparing shHSP90#1 and shHSP90#2 samples to control.   
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Figure 25: HSP90 regulates OGT expression only in the presence of MYC.(A) 
MCF10A-control and MCF10A-cMYC cells containing control, or shHSP90 -1 plasmids 
were analyzed by western blot with the indicated antibodies. (B) Quantification of protein 
expression from conditions in (A). Mean +/- SE *p<0.05. 
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Figure 26: OGT expression and O-GlcNAcylation are elevated in MMTV-MYC 
tumor compared to normal adjacent tissue (A) Western blot analysis of protein 
extracted from tissue collected from MMTV-MYC normal adjacent mammary, 
hyperplastic and tumor tissue analyzed with the indicated antibodies. B) Quantification of 
OGT protein expression from conditions in (A). Mean +/- SE *p<0.05. Western blot 
provided by T. Seagroves, R. Krutilina, L. Schwab. 
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Figure 27: OGT inhibition induces cell death and ER stress in MTEC-MYC cells 
but not normal mammary epithelia cells (A) Western blot analysis of  MCF10A and 
MTEC-MYC cells (derived from MMTV-MYC tumor) were treated with vehicle control 
(DMSO) or 100uM Ac-5sGlcNAc and analyzed with the indicated antibodies.  
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Figure 28: OGT inhibition induces cell death and ER stress in MTEC-MYC cells 
but not normal mammary epithelia cells (A) Western blot analysis of  MCF10A and 
MTEC-MYC cells (derived from MMTV-MYC tumor) were treated with vehicle control 
(DMSO) or  increasing doses of Ac-5sGlcNAc and analyzed with the indicated 
antibodies.  (B) Viability as determined by absorbance after crystal violet staining of 
MCF10A and MTEC-MYC cells treated with control or increasing doses of Ac-
5sGlcNAc. Mean +/- SE *p<0.05. 
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Figure 29: OGT inhibition induces cell death and ER stress in MTEC-MYC cells 
but not normal mammary epithelia cells (A) Crystal violet staining of MCF10A and 
MTEC-MYC cells treated with control or increasing doses of Ac-5sGlcNAc. (B) 
Representative images of immunofluorescent stained 3D cultured MCF10A and MTEC-
Myc cells treated with vehicle control (DMSO) or increasing doses of Ac-5sGlcNAc for 
48 hours.  
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Figure 30: Model of OGT regulation in breast cancer cells via 
PI3K/mTOR/MYC/HSP90 Signaling through RTKs activating PI3K/AKT/mTOR is 
required and sufficient for OGT upregulation through c-MYC and HSP90 stabilizing 
OGT protein. c-MYC itself is O-GlcNAcylated which promotes c-MYC expression and 
generates a feed forward loop promoting tumor growth.  
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3.4 Discussion 
Elevation of O-GlcNAcylation has been implicated in a wide range of cancers. 
However, the pathways responsible for the regulation of OGT and the O-GlcNAc 
modification in cancer cells remained unclear. Here, we show for the first time that the 
PI3K/mTOR pathway via regulation of the oncogenic transcription factor c-MYC is 
responsible for increased OGT and O-GlcNAcylation levels observed in breast cancer 
cells. We demonstrate that,the AKT/mTOR, but not MEK/ERK, pathways were sufficient 
to elevate OGT and O-GlcNAcylation. We found that elevation of OGT and O-
GlcNAcylation in cancer cells is regulated by the oncogenic transcription factor c-MYC. 
c-MYC is both required and sufficient to elevate OGT protein levels and global O-
GlcNAcylation in breast cancer cells. Importantly, we found that c-MYC driven tumor 
cells also displayed elevated OGT and O-GlcNAcylation in vivo. Our data is consistent 
with previous work showing that c-MYC can regulate total O-GlcNAcylation as Rat1A 
myc
+/+
 fibroblasts contained increased O-GlcNAcylation compared to Rat1A myc
-/-
 cells 
[132]. However, this change in O-GlcNAcylation in Rat1A cells was not associated with 
changes in OGT expression as found in our study. It is likely that c-MYC also contributes 
to the supply of essential substrates required for hexosamine biosynthesis as c-MYC can 
increase glucose and glutamine flux in these cells [132] as well as in cancer cells [108].  
Interestingly, c-MYC regulates OGT at the post-transcriptional level as we did not 
detect changes in OGT mRNA expression in cells with altered c-MYC or PI3K/mTOR 
pathways. This may help explain why OGT RNA levels are not found to be elevated in 
breast cancer microarray analysis [76]. Although c-MYC is commonly known for its role 
as a transcription factor, it has been shown to stabilize protein levels of the enzyme 
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glutaminase without affecting RNA expression levels [133]. c-MYC also directly 
increases transcription of the heat shock protein HSP90A [128] which plays an important 
role in protein folding, degradation and maturation. HSP90A is also known to stabilize a 
subset of kinases, steroid receptors, and transcription factors, which are overexpressed in 
cancers [134]. It was recently demonstrated that HSP90A directly interacts with OGT, 
and inhibition of HSP90 reduces the half-life of the OGT protein, leading to decreased 
global O-GlcNAcylation in endothelial cells [40]. Consistent with this data, we showed 
that MYC–induced regulation of OGT, in part, requires HSP90A expression in cancer 
cells. Therefore, we propose a model (Figure 30) in which MYC regulation of OGT 
occurs via its transcriptional activation of HSP90A which facilitates maintenance of OGT 
protein through stabilization or prevention of degradation by the proteasome.  
Previous studies have found that c-MYC can be O-GlcNAcylated [53, 135] in normal 
cells, and more recently in prostate cancer cells [70]. Reducing O-GlcNAcylation in PC-3 
prostate cancer cells leads to reduced c-MYC protein O-GlcNAcylation, decreased c-
MYC stability and was associated with decreased growth and survival of prostate cancer 
cells [70]. HSP90A has also been shown to be O-GlcNAcylated [136]. These data, 
together with our results, suggest that c-MYC, HSP90A and OGT/O-GlcNAcylation may 
be part of a feed-forward-regulatory loop present in cancer cells (Figure 30). 
Amplification of c-MYC in cancer cells can transcriptionally induce HSP90A expression 
leading to increased OGT levels and total O-GlcNAcylation (Figure 30) that feeds back 
to O-GlcNAcylate c-MYC, increasing its stability and thus enabling cancer cell growth. 
Consistent, with this idea, we show that MYC overexpression leads to elevated HSP90A 
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protein levels that are required for increased OGT and O-GlcNAcylation levels. 
Importantly, we show that OGT is required for MYC-mediated cancer cell survival. 
Targeting c-MYC as a cancer therapeutic has proved to be incredibly challenging. 
Direct targeting has yielded few positive results however attempts persist. The most 
encouraging results were recently generated through targeting the MAX binding domain 
on c-MYC [107]. A small molecule screen identified one particular compound, 10058-
F4, that inhibits c-MYC transcriptional activity and elicits cancer cell apoptosis in vitro 
[137]. Despite promise from in vitro studies, this compound fell short of expectation in 
animal models and requires further improvement [138]. Other promising strategies for 
targeting MYC lie in indirectly blocking transcriptional activity by disrupting the 
bromodomain and extra-terminal (BET) coactivator protein BRD4 [107]. Our results 
suggest that OGT may also serve as a potential therapeutic target in MYC-amplified 
breast cancers, and potentially other cancers with amplification of this oncogene, such as 
prostate, neuroblastoma and multiple myeloma. Since increased O-GlcNAcylation can 
also positively regulate c-MYC and other oncogenic transcription factors including 
FoxM1 [59, 60] as well as HIF-1α [76], reducing O-GlcNAcylation in cancer cells via 
OGT inhibition may be an important therapeutic option for a number of cancers. We also 
feel that investigation of the use of OGT inhibitors should be performed in combination 
with therapeutic agents targeting HSP90, more than a dozen of which have at least 
entered clinical trials [139].  
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CHAPTER 4: O-GLCNACYLATION AND OGT REGULATE LIPID 
METABOLISM IN BREAST CANCER 
4.1 Introduction 
4.1.1 Warburg Effect: Fatty Acid Metabolism  
Most work describing the mechanism of lipid synthesis and regulation of lipid 
homeostasis has been conducted in the highly lipogenic tissue of the liver [140].  
Increasing evidence indicates that cancer cells display specific alterations in pathways 
that drive lipogenesis to support membrane synthesis and generate signaling molecules 
required for rapid cell growth [86]. Most normal adult tissues obtain lipids from the 
bloodstream in the form of dietary free fatty acids, however, cancer cells reactive de novo 
lipogenesis, a process normally turned off after development [141]. Production of lipids 
functions to build new membranes, serve as signaling molecules and contribute to post-
translational modifications (Figure 31B) [86]. This consists of activation and expression 
of enzymes involved in generating lipids, that are normally expressed at low levels in 
most adult tissues, such as Fatty acid synthase (FAS), Acetyl-CoA carboxylase (ACC), 
and ATP-citrate lyase (ACLY) as well as a transcription factor responsible for these 
enzymes, Sterol regulatory element binding protein (SREBP-1) [142]. The SREBP-1c 
and SREBP-2 transcription factors are known to regulate many proteins involved in lipid 
and cholesterol synthesis, respectively, while the SREBP-1a isoform is an activator of all 
SREBP-responsive genes [140]. SREBP family transcription factors are synthesized as 
inactive precursors which reside in the endoplasmic reticulum (ER) membrane and 
nuclear envelope (Figure 32B) [140]. Upon decreases in sterol or lipid levels, [143] these 
66 
 
proteins are bound by SREBP-cleavage activating protein (SCAP) and proteolytically 
cleaved generating an N-terminal region containing the basic helix-loop-helix–leucine 
zipper (bHLH-Zip) for DNA binding [140]. Mature SREBPs can then enter the nucleus 
and associate with Sterol Regulatory Element (SRE) regions of target gene promoters. 
Aberrant activation of these genes has been found in various cancer types including 
breast, ovarian, and prostate [144]. It is evident the up-regulation of many of these 
enzymes is accomplished through oncogenic signaling pathways such as Akt/mTORC1 
or altered growth factor receptor signaling [142, 144].  
4.1.2 Lipogenic enzymes and cancer  
Previous studies have shown the necessity for lipogenic enzymes and lipids in cancer cell 
survival. Transcription factor SREBP-1 has been identified as an important contributor to 
cancer phenotypes and survival through its activation of lipid synthetic enzymes such as 
FAS, ACLY, ACC, and SCD1 (stearoyl-CoA desaturases), many of which are rate 
limiting enzymes in lipid synthesis pathways (Figure 32A) [142, 145]. SREBP-1 
overexpression has been found in colorectal, prostate, breast, endometrial and 
hepatocellular carcinoma [146] and knockdown of SREBP-1 in endometrial cancer cells 
resulted in significant cell death in vitro and slowed tumor growth in vivo, as well as 
induced cell death in glioblastoma cells in culture [62]. ACLY, a key lipogenic enzyme 
and transcriptional target of SREBP-1, has displayed increased activity and expression in 
various cancers [141, 144, 147-149] and suppression of this enzyme results in the 
induction of cancer cell growth arrest or death, thereby supporting it as a possible 
therapeutic target [150-152]. ACLY has also been shown to be required for cellular 
transformation in vitro and in vivo [150] demonstrating its significance in maintaining 
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cancer phenotypes. The use of acetyl-CoA in acetylation can directly affect cell 
metabolism, as glucose dependent acetylation of histones, which regulates expression of 
glycolytic enzymes, requires ACLY in adipocytes [153]. Another transcriptional target of 
SREBP-1, FAS, has been examined as a therapeutic target in cancer as inhibition of this 
enzyme results in apoptosis in vitro and in vivo in breast cancer models [154].  
 AMPK is an important metabolic sensor that is implicated in cancer growth and 
survival [155]. This kinase has been well characterized in tissues such as liver and 
skeletal muscle for its role in halting anabolic processes in response to AMP/ATP ratio 
changes. AMPK activation occurs in response to a variety of cellular stressors including 
low glucose and depletion of ATP levels [155]. Downstream of AMPK, mTOR and other 
drivers of cellular growth are directly phosphorylated to inhibit their synthetic actions 
within cells to ration energy and substrates [156]. Expression of a dominant negative 
AMPK results in acceleration of prostate cancer cells and restoration of AMPK activity 
in LKB1 deficient lung cancer cells through reconstitution of wild-type LKB1 results in 
inhibition of cancer cell growth [155]. Together, these demonstrate the importance of 
AMPK in cancer and its value as a potential tool in the treatment of cancer. AMPK 
directly regulates lipid metabolism in hepatic, muscle and adipose tissue through 
phosphorylation of SREBP-1 and ACC, and indirect regulation of PGC1α and PPARs 
resulting in changes in lipid synthesis and lipolysis [157, 158]. Due to its centralized 
position within highly cancer related networks, its direct relationship with mTOR 
signaling, and its role in regulating processes essential to cancer survival, it has become 
an area of interest in cancer research and a treatment focus [159].  Its tumor suppressive 
role is well documented in a variety of cancers through its regulation of mTOR, 
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ACC/FAS and inflammation; however a direct connection to SREBP-1 in cancer has not 
yet been established.  
Several studies have provided evidence that inducing metabolic stress in cancer cells, 
such as that resulting from glucose deprivation or treatment with 2-deoxy-D-glucose, 
leads to the accumulation of unfolded proteins, endoplasmic reticulum (ER) stress and 
death [160, 161]. Nutrient deprivation activation of apoptotic mediators (such as the Bcl-
2-family BH3-only proteins Noxa, Puma and Bim) in response to nutrient stress has been 
linked to the induction of the unfolded protein response (UPR) in the endoplasmic 
reticulum [162]. The UPR is characteristically exploited by cancer cells as a necessary 
mechanism for supporting survival as it reduces the burden on the ER caused by 
persistent elevated levels of unfolded proteins [163]. Cancer cells are highly dependent 
on the metabolic pathways driving the Warburg effect as well as pathways such as the 
UPR which allow for survival of these cells under highly stressful circumstances. 
Therefore it stands to reason that targeting pathways that regulate cancer cell metabolism 
and their coping strategies could be a way to induce cell death. Indeed, we are not the 
first to postulate that exploiting this reliance could be used as a therapeutic. It has been 
shown previously that inhibition of a variety of enzymes important to metabolic 
pathways, such as glycolysis, decrease cancer phenotypes, alone or in combination [164, 
165]. Previous studies determined that inhibiting proteins important to lipogenesis, 
SREBP-1 and ACLY, in cancer cells induced ER stress resulting in cell death [62, 166].  
The complex regulation of SREBP-1 allows a window of opportunity, lacking for most 
transcription factors, in which SREBP-1 can be inhibited. Kamisuki has shown that the 
inhibitor fatostatin binds SREBP-cleavage activating protein (SCAP) resulting in 
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decreased mature SREBP-1 (as well as SREBP-2) and the transcriptional targets of these 
factors [167, 168]. This drug has shown efficacy in reducing prostate cancer cell growth 
as well as tumor size in an in vivo model [167] as well as reduced 3D morphology of 
several breast cancer cell lines [169].   
4.1.3 OGTs connection to lipids in other systems 
Links between OGT and lipids exist in normal and diseased biology. As noted 
previously, OGT contains a phosphoinositide binding domain (PPO) demonstrated to 
have activity in protein-lipid binding to several lipid species [13]. In response to insulin 
stimulation, the PIP3 binding domain in OGT has been shown to recruit OGT to the cell 
membrane [13]. In the liver, OGT was shown to directly interact with and O-GlcNAc 
modify ChREBP (Carbohydrate responsive element binding protein) stabilizing this 
transcription factor to promote activation of lipogenic genes [170].    
Here, we demonstrate a connection between nutrient sensor O-GlcNAcylation and lipid 
synthesis in cancer. Our results show that OGT and O-GlcNAcylation are required for 
lipid synthesis in breast cancer cells through the regulation of SREBP-1 in an AMPK-
dependent manner. OGTs regulation of cancer growth and survival requires SREBP-1 
expression and its control of lipids, as restoring SREBP-1 expression in the context of 
OGT inhibition prevented cancer cell death in vitro and restored tumor growth in vivo. 
Thus, O-GlcNAcylation serves to link cancer cell nutritional status to lipid metabolism 
and cell survival via regulation of SREBP-1. 
4.2 Results 
4.2.1 O-GlcNAcylation regulates lipid metabolism in breast cancer cells  
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To understand the impact of O-GlcNAcylation on cancer metabolism, global 
metabolomics analysis using liquid and gas chromatography-mass spectrometry (LC-
MS/GC-MS) was utilized to investigate the effect of OGT reduction on metabolites in 
triple-negative human breast cancer cells MDA-MB-231. The metabolic analysis of 
MDA-MB-231 cells containing OGT RNAi for 48 hours (Figure 33A) demonstrated 
statistically significant (p<0.05) changes in 124 out of 301 metabolites examined when 
compared to control RNAi cells (Figure 34B). The effects of reducing OGT levels in 
cancer cells on carbohydrate metabolism have been reported elsewhere [21].  Levels of 
the branched-chain amino acids (BCAA) isoleucine and leucine were significantly 
reduced with OGT knockdown, while valine demonstrated a non-significant reduction 
(Figure 38A).  These decreases may reflect increased catabolism as levels of several 
BCAA catabolites were significantly elevated in cells where OGT was suppressed, as 
compared to control cells. These included 4-methyl-2-oxopentanoate, 3-methyl-2-
oxovalerate, isovalerylcarnitine, 2-methylbutyrylcarnitine, and isobutyrylcarnitine 
(Figure 38A). We also found decreases in histidine, lysine, phenylalanine and tyrosine 
metabolites when OGT was suppressed (Figure 38A). Nicotinate and nicotinamide 
metabolites as well as nucleotide sugars and pentose and purine metabolites also 
significantly decreased in MDA-MB-231-shOGT cells compared to MDA-MB-231-
control (Figure 39A).  
The largest change in metabolites, upon reduction of OGT levels in cancer cells, was in 
lipids. Of the lipid metabolites measured, 43% significantly decreased following OGT 
inhibition, compared to decreases in 27% of the measured amino acids, decreases in 21% 
of the carbohydrate metabolites and 14% of nucleotides (Figure 34B). Levels of free fatty 
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acids, including the polyunsaturated fatty acid linoleate (that cannot be generated by 
mammalian cells), decreased significantly in shOGT-treated cells compared to control 
cells (Figure 35A-36A).  The idea of decreased uptake of essential fatty acids was 
supported by significant decreases in a variety of other essential fatty acids with OGT 
inhibition as well as decreased intake of a fluorescent C16 lipid mimetic in shOGT cells 
compared to control (Figure 40B-C). Similar to free fatty acids, several lysolipids and a 
number of long chain fatty acids were less abundant in shOGT cells, as compared to 
control cells at 48 hours (Figure 36A, 37A). In response to OGT inhibition, decreased 
free fatty acid pools may result in reduced phospholipid synthesis and/or increased fatty 
acid mobilization from phospholipids resulting in the observed decrease in lysolipids. 
Carnitine metabolites increased with OGT suppression indicating that beta-oxidation may 
be increased (Figure 40A). Due to the immense body of literature relating to the 
requirement of lipid synthesis for cancer growth and survival we aimed to confirm 
metabolomics profiling results relating to de novo lipogenesis (Figure 35A). To achieve 
this we measured  free fatty acids in MDA-MB-231 cells and found a ~50% decrease in 
free fatty acid levels in OGT knockdown cells compared to control cells (Figure 41A-B). 
We found a similar reduction of free fatty acid levels in the breast cancer cell lines MCF-
7 (Figure 45B), BT474 (ER+/ErbB2+) (Figure 48B), and SUM-159 (Figure 47B) stably 
expressing OGT RNAi compared to control cells. In addition, cancer cells MDA-MB-231 
(Figure 41C) and MCF-7 (Figure 45C) also contained lower levels of intracellular lipid 
droplets as measured by nile red staining (fluoresces in large hydrophobic cores of lipid 
droplets and has minimal interaction with cellular membranes) when OGT was 
suppressed [171]. Conversely, overexpression of OGT in MCF-7 cells (Figure 42A) 
72 
 
significantly increased free fatty acid levels (Figure 42B) and nile red staining (Figure 
49A). Treatment of MDA-MB-231 cells with the OGT pharmacological inhibitor Ac-
5sGlcNAc also resulted in a significant decrease in free fatty acids (Figure 43A) and lipid 
droplets (Figure 43B).  To determine if lipids contribute to OGT-mediated phenotypes of 
cell growth, we treated MDA-MB-231 cells stably expressing OGT RNAi with 
exogenous lipids (palmitate/oleic acid). Treatment with exogenous lipids partly rescued 
growth defects resulting from OGT suppression (Figure 44A) and reduced levels of 
apoptotic marker cleaved PARP (Figure 44B). These data suggest a decrease in rates of 
fatty acid synthesis as a result of reduced O-GlcNAcylation contributes to growth defects 
in breast cancer cells. Thus, O-GlcNAcylation regulates levels of lipid metabolites and 
free fatty acids in breast cancer cells.   
4.2.2 O-GlcNAcylation regulates master lipid regulator SREBP-1 and lipid enzymes 
in breast cancer cells  
SREBP-1 is a critical regulator of lipid metabolism and in cancer cells is responsible for 
sustaining  necessary production of lipids [141]. To examine whether O-GlcNAcylation 
may regulate lipid metabolism via SREBP-1, we first asked whether expression of 
SREBP-1, OGT and global O-GlcNAcylation change as mammary tumors progress in a 
spontaneous breast cancer model in vivo. To achieve this, we examined tissue throughout 
progression of breast tumor formation in the MMTV-PyMT transgenic breast cancer 
mouse model. Mammary hyperplasia can be detected in this model as early as 4 weeks 
and a large percentage of mice developed carcinoma at ∼14 weeks [172] (Figure 45A). 
Protein expression of OGT and O-GlcNAcylation levels increased notably from week 8 
to 12 during progression in this tumor model. Correlating with this increase, we found 
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nuclear SREBP-1 protein (N) levels and its transcriptional target ACLY increase during 
this time frame (Figure 45B). Consistent with increased SREBP-1 expression in the 
MMTV-PyMT derived mammary tissue, nile red staining was increased in MMTV-
PyMT derived mammary gland at week 8 compared to a wildtype mouse mammary gland 
of the same background (Figure 45C).  
To directly examine whether O-GlcNAcylation regulates SREBP-1 and lipogenic 
enzymes in breast cancer cells, we targeted OGT both genetically and pharmacologically. 
Inhibition of OGT via RNAi in breast cancer cells MDA-MB-231 (Figure 46A-B), MCF7 
(Figure 48A, 52A), and SUM159 (Figure 50A, 51A, 52B) results in decreased protein 
expression of both the ER transmembrane precursor (P) and the cleaved nuclear 
transcription factor form of SREBP-1 (N). Consistent with a decrease in SREBP-1 
expression, OGT inhibition resulted in decreased protein expression of SREBP-1 
transcriptional targets ACLY and FAS in MDA-MB-231 (Figure 46A), MCF-7 (Figure 
48A) and SUM-159 (Figure 50A) breast cancer cell lines. MDA-MB-231 cells stably 
expressing OGT RNAi also contain decreased levels of mRNA of SREBP-1 
transcriptional targets FASN, ACLY, ELOVL7 (ELOVL Fatty Acid Elongase 7), ACC and 
LPL (Lipoprotein Lipase) compared to controls (Figure 47A). Pharmacological inhibition 
of OGT using Ac-5sGlcNAc resulted in reduced total O-GlcNAcylation and similar 
decreases in SREBP-1 and FAS in MBA-MB-231 cells (Figure 47B). Conversely, 
overexpression of OGT in MCF-7 cells increased SREBP-1 protein levels as well as 
levels of ACLY and FAS (Figure 47C, 49B) consistent with increased nile red (Figure 
49A) and free fatty acid levels (Figure 42B).  
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Project Achilles contains organized data about requirement for viability in hundreds of 
different cells lines after genetic deletion using shRNA or CRISPR targeting a large 
quantity of genes. These “gene requirement” or “essentiality scores” define the 
requirement of expression of a particular gene for survival of cancer cells.  When 
searching these genome scale pooled shRNA screening data for breast cancer cell lines 
requirement of OGT and comparing to lipid related genes with similar essentiality scores 
we found correlation to FASN, ACLY, ACC, Sphingolipid delta 4 desaturase (DEGS1), 
and Pyruvate Dehydrogenase (polyamide) beta (PDHB) using Pearson correlation and 
Spearman rank correlation. We also found correlation to the glycolytic enzyme ENO1 as 
well as HIF1α which we have previously found to be regulated by OGT thereby 
increasing our confidence in our findings that cancer cells have a similar requirement for 
expression of OGT and the lipogenic genes listed above (Figure 53) [21].    
4.2.3 O-GlcNAcylation regulates SREBP-1 expression in a proteasomal and AMPK-
dependent manner 
We next examined the mechanism by which OGT and O-GlcNAcylation regulates 
SREBP-1 in cancer cells. SREBP-1 protein can be regulated by proteasomal degradation 
[173] thus we examined whether O-GlcNAc regulation is proteasome-dependent. 
Treatment of breast cancer cells with proteasomal inhibitor MG132 blocked the OGT 
suppression-induced decrease in nuclear SREBP-1, and to a lesser extent precursor 
SREBP-1 compared to control (Figure 54B) and reversed decreases in SREBP-1 
transcriptional target ACLY (Figure 54B). While SREBP-1 mRNA was decreased upon 
OGT inhibition this could be a consequence of SREBP-1 protein levels as it 
transcriptionally controls itself. We chose to mechanistically pursue regulation of 
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SREBP-1 protein by OGT. SREBP-1 does not appear to be directly O-GlcNAcylated as 
immunoprecipitation of exogenous SREBP-1 contained no detectable O-GlcNAcylation 
when compared to a known target (data not shown). This does not rule out the possibility 
that SREBP-1 is O-GlcNAc modified but suggests that O-GlcNAcylation may regulate 
SREBP-1 protein stability indirectly. 
We have previously demonstrated that reduction of OGT via RNAi, in breast cancer 
cells, results in metabolic stress and leads to activation of the AMPK pathway [21]. 
AMPK is activated under low nutrient conditions to inhibit mTOR and downstream 
pathways thereby reducing mitogenic signaling. Reducing O-GlcNAcylation leads to an 
increase in phosphorylated AMPK (T172), an indicator of activated AMPK, as well as a 
decrease in mTOR signaling [76]. AMPK is known to phosphorylate SREBP-1 on 
Ser372 and inhibit its cleavage and maturation in hepatocytes [158]. Thus, we examined 
whether OGT may regulate SREBP-1 in an AMPK-dependent manner. Using a phospho-
antibody that recognizes SREBP-1 phosphorylation on Ser372, we observe an increase in 
SREBP-1 phosphorylation when OGT is suppressed in MDA-MB-231 cells, correlating 
with activation of AMPK as measured by phosphorylation at T172 (Figure 55A). We 
tested the requirement of AMPK in OGT-mediated changes in SREBP-1 in MDA-MB-
231 cells by treating cells with the AMPK inhibitor Compound C. MDA-MB-231 cells 
treated with Compound C contained decreased AMPK phosphorylation and activation as 
measured by phosphorylation of its substrate Raptor (Ser792) compared to control cells. 
The reduced SREBP-1 protein levels observed upon suppression of OGT were partly 
reversed by treatment with Compound C (Figure 57A right, 54A). Similar results were 
obtained in MDA-MB-157 cells (Figure 57A left) suggesting that OGT regulation of 
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SREBP-1 is AMPK-dependent in multiple breast cancer cells. We then assessed whether 
regulation of SREBP-1 by OGT required AMPK using WT and AMPK-/- mouse 
embryonic fibroblasts (MEFs). In WT MEFs, OGT inhibition results in decreased 
SREBP-1 protein expression and transcriptional targets ACLY and FAS, consistent with 
our observations in breast cancer cell lines (Figure 56A). However, AMPK null MEFs 
showed little change in SREBP-1, ACLY and FAS protein expression upon OGT 
inhibition. Thus, regulation of SREBP-1 by OGT is, at least partially, AMPK dependent 
(Figure 56-57).  Addition of methyl pyruvate after OGT suppression reversed activation 
of AMPK and SREBP-1 phosphorylation and restored total levels of SREBP-1 to that of 
control cells (Figure 56B). SREBP-1 is known to be degraded by the proteasome and is 
bound by the E3 Ubiquitin ligase FBXW7. Others have demonstrated that 
phosphorylation of SREBP-1 by GSK3β precedes interaction with the tumor suppressor 
and E3-ubiquitin ligase FBXW7 [173, 174]. We examined expression of FBXW7 
(FBW7) in MDA-MB-231 cells and determined that basal protein levels increased when 
OGT was suppressed via RNAi (Figure 58A). Due to the known requirement of GSK3β 
in FBW7- dependent degradation of SREBP-1, we treated cells with the GSK3β inhibitor 
SB216763. Addition of this compound to MDA-MB-231-shOGT cells prevented a 
decrease in SREBP-1 nuclear protein (Figure 58B) indicating that GSK3β may be 
necessary for OGT regulation of SREBP-1. Immunoprecipitation revealed that interaction 
between SREBP-1 and FBW7 increased when OGT was inhibited (Figure 59A-B). This 
data implies that mechanisms for degrading SREBP-1 are also partly responsible for 
OGT regulation of SREBP-1 protein.  
77 
 
4.2.4 O-GlcNAcylation-mediated cancer cell survival requires SREBP-1 regulation 
of lipid and glucose metabolism in cancer cells 
To determine if changes in SREBP-1 were required for the lipid defects observed upon 
OGT inhibition, we overexpressed exogenous SREBP-1 to restore levels in the context of 
OGT knockdown.  While SREBP-1 nuclear protein levels were still affected by OGT 
suppression in cells where exogenous SREBP-1 was expressed, they were comparable to 
levels in control cells thereby ensuring that SREBP-1 had been restored to basal levels 
(Figure 61A-B). Cells stably overexpressing exogenous SREBP-1 significantly restored 
free fatty acid levels (Figure 60A) and nile red staining (Figure 60B) in OGT knockdown 
cells to levels similar to control cells. Consistent with a rescue in free fatty acids, 
overexpression of SREBP-1 rescued protein levels of transcriptional targets ACLY and 
FAS in OGT knockdown cells compared to controls (Figure 61A). This indicated that 
decreases in lipid droplets and free fatty acid levels resulting from OGT suppression were 
due to OGT effects on SREBP-1 protein levels. 
 We have previously shown that OGT suppression in MDA-MB-231 cells results 
in inhibition of growth and survival [76]. We next tested whether regulation of SREBP-1 
by OGT played a role in cancer cell survival. Growth inhibition resulting from OGT 
suppression was partially reversed by re-expressing SREBP-1 (Figure 62A). We have 
also previously reported that OGT inhibition decreased soft agar colony formation [59]. 
This measure of anchorage-independent growth was restored when SREBP-1 was 
expressed in OGT knockdown MDA-MB-231 cells, as was growth in 3D culture (Figure 
62A, 63A-B). Apoptotic factors such as cleaved caspase 3 and cleaved PARP, which are 
78 
 
induced upon OGT suppression, were no longer activated with SREBP-1 restoration and 
the loss of anti-apoptotic Bcl2 was prevented in these cells (Figure 62B).  
 Although exogenous lipids were able to partially prevent decreased cell growth 
upon OGT knockdown cells (Figure 44A), we noticed that SREBP-1 overexpression 
rescued growth to an even greater extent (Figure 62A). Since we have previously shown 
that OGT regulates HIF-1α and its transcriptional target GLUT1, and overexpression of a 
HIF-1α stable mutant or GLUT1 can also fully rescue OGT knockdown phenotypes, we 
examined expression of HIF-1α and GLUT1 in SREBP-1 overexpressing cells. In cells 
overexpressing SREBP-1 we did not detect any changes in HIF-1α however, surprisingly, 
we found maintenance of GLUT1 in OGT knockdown cells (Figure 64A). Consistent 
with the idea that SREBP-1 overexpression may be regulating GLUT1 function, we 
found that glucose uptake inhibition caused by OGT-knockdown was reversed in 
SREBP-1 overexpressing cells (Figure 64A). Similar reversal was seen in lactate 
production suggesting that SREBP-1 can also regulate OGT-mediated glycolytic flux 
(Figure 65A-B).  It makes sense that in order for exogenous SREBP-1 protein expression 
to restore relative free fatty acid levels in the context of OGT knockdown that not only 
would expression of lipogenic enzymes be required, but also a  replenishment of 
substrates for the synthesis of lipids.   
 We next examined if signaling through growth pathways such as mTOR were 
restored by SREBP-1 re-expression. Indeed, SREBP-1 expression prevented decreases in 
mTOR signaling seen with OGT suppression in control cells, as measured by 
phosphorylated 4EBP-1 and S6 Ribosomal protein (Figure 64A). Downstream of mTOR, 
c-Myc protein expression was also rescued by SREBP-1 over-expression which may 
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explain the restoration of GLUT1 (Figure 64A). Restoration of the mTOR signaling 
pathway and c-Myc are consistent with a restoration in glycolytic flux, showing that re-
establishing SREBP-1 expression in the context of OGT suppression allows for cell 
growth and metabolic signaling characteristics consistent with control cells. We noted 
that in agreement with these changes in mTOR signaling we also see a reversal of 
activation of AMPK as measured by phospho-AMPK (T132) which occurs with 
decreased OGT (Figure 64A). SREBP-1 re-constitution also prevented the increase in 
intracellular ROS following OGT inhibition which may be due to SREBP-1 regulation of 
G6PD (Figure 66A) [175]. Whether this has any bearing on or contribution to survival 
has yet to be determined. Interestingly, several other signaling pathways were also 
rescued by SREBP-1 restoration in conditions of OGT suppression including ERK 
activation (to a much lesser extent than mTOR pathway activation) as well as preventing 
activation of stress pathway P38 MAPK (Figure 66B). Basal ERK activation was also 
elevated solely by increasing SREBP-1 expression in MDA-MB-231 cells. There was 
also a lack of activation of DNA damage/ double strand breaks, as measured by H2Ax 
phosphorylation, upon OGT suppression when SREBP-1 was present (Figure 66B). ER 
stress activation previously reported as a consequence of OGT inhibition was not 
prevented by SREBP-1 overexpression. SREBP-1 overexpressing cells in fact had higher 
expression of several proteins induced by activation of ER stress than the basal levels 
displayed in control cells, including phospho-eif2α, and BIM (Figure 67A). Using stable 
isotope labeling in MDA-MB-231 cells we were unable to show that OGT inhibition 
decreased the use of glucose in the synthesis of fatty acid palmitate. C
13
-Glucose 
containing media was fed to MDA-MB-231 cells expressing control or OGT shRNA for 
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48 hours. Lipids were then extracted from equal cell numbers from each condition and 
subjected to fatty acid methyl ester analysis (FAME). The final step (GC-MS) then 
analyzed palmitate species. These results confirmed that unlabeled palmitate was 
decreased by OGT suppression. However, in MDA-MB-231 shOGT cells, glucose was 
still used to generate newly synthesized palmitate, to a greater extent than control cells 
when comparing some labelled species (Figure 68A). It is possible that glutamine use in 
lipid synthesis is affected more by OGT manipulation as we have yet to determine if 
glucose or glutamine contributes more to this synthetic process in these cells. These 
results demonstrate that SREBP-1 is an important downstream effector of OGT-
suppression induced phenotypes in breast cancer. These include; decreased lipogenic 
factors, induction of apoptosis, decreased glycolytic factors and metabolic changes. 
4.2.5 SREBP-1 is critical for OGT-mediated regulation of breast cancer 
tumorigenesis in vivo 
To determine if the regulation of SREBP-1 by OGT was important for tumor growth and 
survival in vivo, we employed an orthotopic xenograft animal model. We injected MDA-
MB-231- Luciferase cells containing control vectors, stable OGT suppression, or cells 
containing exogenous SREBP-1 overexpression with and without OGT suppression into 
the inguinal fat pad of female 6-8 week old Nu/Nu mice. We monitored tumor growth as 
a readout of bioluminescence intensity and using caliper measurements.  At animal 
endpoint we observed a significant rescue of tumor volume when SREBP-1 was restored 
compared to tumors where OGT was stably suppressed (Figure 69A-B, 70A).  This result 
establishes that SREBP-1 is an important downstream effector of OGT in the promotion 
of cancer cell growth in vivo.  
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4.3 Figures and Figure Legends 
 
Figure 31: Model of cellular contributions to the free fatty acid pool and importance 
of fatty acids (A) Arrows indicate decreases (red) and increases (green) in processes that 
could result in increases in the free fatty acid pool within cells.  (B) Diagram 
demonstrating how fatty acids contribute to cancer cell growth and survival. Inhibition of 
enzymes in lipogenesis has been determined to decrease cancer cell viability.  
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Figure 32: Model of SREBP-1 transcriptional control of lipogenesis and SREBP-1 
cellular localization (A) Signaling through RTKs activating PI3K/AKT/mTOR is 
required and sufficient for OGT upregulation through c-MYC and HSP90 stabilizing 
OGT protein. c-MYC itself is O-GlcNAcylated which promotes c-MYC expression and 
generates a feed forward loop promoting tumor growth.  
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Figure 33: Significant changes occur in metabolites from all superpathways listed in 
MDA-MB-231 cells upon OGT suppression. Heat map displaying decreased values 
(green) and increased (red) metabolites in MDA-MB-231 cells comparing control 
(purple) to cells where OGT has been suppressed via RNAi for 48 hours (yellow).  
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Figure 34: Significant changes occur in metabolites from all metabolite categories 
shown in MDA-MB-231 cells upon OGT suppression. (A) MDA-MB-231 cells 
expressing control and shOGT plasmids were analyzed via western blot using the 
indicated antibodies. (B) Pie charts displaying significant changes found in metabolites 
categorized as amino acids, carbohydrates, lipids and nucleotides when comparing MDA-
MB-231 control and shOGT cells analyzed via LC-MS. Unchanged metabolites (blue), 
decreased metabolites (red) and increased metabolites (green). Mean +/- SE *p<0.05. 
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Figure 35: Significant decreases occur in many lipid metabolites in MDA-MB-231 
cells upon OGT inhibition MDA-MB-231 cells expressing control and shOGT plasmids 
were analyzed via LC-MS. Mean +/- SE *p<0.05, ** p< 0.005. 
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Figure 36: Changes in essential fatty acid and carnitine metabolites in MDA-MB-
231 48 hours after OGT inhibition  Carnitine and essential fatty acid metabolite 
changes comparing MDA-MB-231-control and MDA-MB-231-shOGT as analyzed via 
LC-MS or GC-MS. Significant decreases (dark green) and increases (dark red) p<0.05 
and nearly significant decreases (light green) and decreases (pink) p>0.05.  
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Figure 37: Changes in fatty acid metabolites in MDA-MB-231 48 hours after OGT 
inhibition MDA-MB-231 cells expressing control and shOGT plasmids were analyzed 
via LC-MS or GC-MS. Mean values for measured metabolite from MDA-MB-231-
shOGT normalized to MDA-MB-231-control. Significant decreases (dark green) and 
increases (dark red) p<0.05 and nearly significant decreases (light green) and decreases 
(pink) p>0.05.  
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Figure 38: Changes in metabolites in MDA-MB-231 48 hours after OGT inhibition 
MDA-MB-231 cells expressing control and shOGT plasmids were analyzed via LC-MS 
or GC-MS. Mean values for measured metabolite from MDA-MB-231-shOGT 
normalized to MDA-MB-231-control. Significant decreases (dark green) and increases 
(dark red) p<0.05 and nearly significant decreases (light green) and decreases (pink) 
p>0.05.  
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Figure 39: Changes in metabolites in MDA-MB-231 48 hours after OGT inhibition 
MDA-MB-231 cells expressing control and shOGT plasmids were analyzed via LC-MS 
or GC-MS. Mean values for measured metabolite from MDA-MB-231-shOGT 
normalized to MDA-MB-231-control. Significant decreases (dark green) and increases 
(dark red) p<0.05 and nearly significant decreases (light green) and decreases (pink) 
p>0.05.  
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Figure 40: Significant changes occur in essential and carnitine lipid metabolites in 
MDA-MB-231 cells upon OGT inhibition(A) MDA-MB-231 cells expressing control 
and shOGT plasmids were analyzed via LC-MS. Significant increases in carnitine 
metabolites between control (red) and  shOGT (blue) MDA-MB-231 cells. (B) Essential 
fatty acids measured via LC-MS in MDA-MB-231 control (red) and shOGT (blue) cells. 
(C) Uptake of C16 –fluorescent lipid mimetic in MDA-MB-231 control, shOGT1 and 
shOGT2 cells as measured via FACS. Mean +/- SE *p<0.05, ** p< 0.01, ***p<0.005. 
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Figure 41: OGT inhibition decreases free fatty acids and lipid droplets in MDA-MB-
231 cells (A) Free fatty acids were isolated and measured from MDA-MB-231 cells 
expressing control, shOGT-1 and shOGT-2 plasmids. (B) Western blot analysis of MDA-
MB-231 control, shOGT-1 and shOGT-2 cells analyzed with the indicated antibodies. (C) 
Representative images of fluorescent imaging of nile red stained MDA-MB-231 control, 
shOGT-1 and shOGT-2 cells.  
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Figure 42: OGT overexpression in MCF7 cells results in increased relative free fatty 
acids (A) Cell lysates from MCF7 cells stably overexpressing control or Flag-OGT were 
collected for western blot analysis with the indicated antibodies. (B) Measurement of 
relative free fatty acids in MCF7 stably overexpressing control or Flag-OGT. Mean ± SE. 
*p<0.05 
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Figure 43: Pharmacological inhibition of OGT decreases free fatty acids and lipid 
droplets in MDA-MB-231 cells (A) Free fatty acids were isolated and measured from 
MDA-MB-231 cells treated with vehicle control (DMSO) or Ac-5sGlcNAc (100uM) for 
24 hours. (B) Representative bright field and immunofluorescence images of nile red 
stained MDA-MB-231 treated with control DMSO or Ac-5sGlcNAc for 24 hours. Mean 
+ SE; * p-value< 0.05. 
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Figure 44: Addition of exogenous lipids partly restores growth in conditions of OGT 
suppression in MDA-MB-231 cells (A) Crystal Violet stained 2D MDA-MB-231 cells 
containing control or stable OGT suppression for 6 days treated with control PBS/BSA 
solution or 100um Sodium Palmitate and 40um Oleic acid in PBS/BSA. (B) Western blot 
analysis of MDA-MB-231 cells representing the conditions in (A) analyzed with the 
indicated antibodies.  
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Figure 45: OGT and SREBP-1 protein expression correlate with tumor progression 
in vivo.  (A) H&E staining of mammary fat pads collected from MMTV-PyMT mice at 
weeks 4, 8, 12 and 14. (B) Cell lysates was collected from mammary fat pad tissue 
collected from MMTV-PyMT mice at 4, 8, 12 and 14 weeks of age for immunoblot 
analysis with the indicated antibodies. (C) Representative images of nile red stained 
mammary fat pad tissue collected from WT and MMTV-PyMT mice at 8 weeks of age.  
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Figure 46: OGT inhibition results in decreased SREBP-1 protein in MDA-MB-231 
cells (A) Cell lysates from MDA-MB-231 cells expressing control, OGT-1 or OGT-2 
shRNA were collected for immunoblot analysis with the indicated antibodies (top). 
SREBP-1 nuclear (N) and precursor (P) are indicated on the left. (B) SREBP-1 protein 
expression was quantified and normalized to actin (below). Mean +/- SE *p<0.01. 
Statistical analysis performed for separate SREBP-1 forms examined comparing shOGT1 
and shOGT2 samples to control.   
97 
 
 
Figure 47: OGT regulates SREBP-1 expression in breast cancer cells (A) 
Measurement of relative mRNA expression of SREBP-1 target genes from control or 
stable OGT shRNA expressing MDA-MB-231 cells using qRT-PCR. (B) Western blot of 
MDA-MB-231 cells treated for 48 hours with control (DMSO) or 100 mM Ac-5s-
GlcNAc analyzed with the indicated antibodies. (C) Western blot analysis of MCF7 cells 
stably overexpressing control or Flag-OGT analyzed with the indicated antibodies. Mean 
± SE. *p<0.05 **p< 0.01. Statistical analysis performed for separate genes examined 
comparing shOGT1 and shOGT2 samples to control.   
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Figure 48: OGT inhibition decreases SRBEP-1, free fatty acids and lipid droplets in 
MCF7 cells (A) Western blot analysis of MCF7 control, shOGT-1 and shOGT-2 cells 
analyzed with the indicated antibodies. (B) Free fatty acids were isolated and measured 
from MCF7 cells expressing control, shOGT-1 or shOGT-2. (C) Representative images 
of fluorescent imaging of nile red stained MCF7 control, shOGT-1 and shOGT-2 cells. 
Mean ± SE. *p<0.05. 
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Figure 49: OGT overexpression increases lipid droplet content and increases 
nuclear SREBP-1 expression (A) Representative images of bright field and nile red 
stained MCF7 cells containing control or Flag-OGT plasmid. (B) Quantification of 
relative SREBP-1 protein expression from immunoblot analysis of MCF7 cells 
containing control or Flag-OGT plasmid. Mean + SE; * p-value< 0.05. 
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Figure 50: OGT inhibition decreases SREBP-1 and free fatty acids in SUM-159 cells 
(A) Western blot analysis of SUM-159 control, shOGT-1 and shOGT-2 cells analyzed 
with the indicated antibodies. (B) Free fatty acids were isolated and measured from 
SUM-159 cells expressing control, shOGT-1 or shOGT-2. Mean ± SE. *p<0.05. 
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Figure 51: OGT inhibition decreases SREBP-1 in SUM-159 cells and free fatty acids 
in BT-474 cells (A) Representative images of immunofluorescence in 3-D culture of 
SUM-159 control and shOGT-1 cells analyzed with the indicated antibodies and stains. 
(B) Free fatty acids were isolated and measured from BT-474 cells expressing control 
and shOGT-1. Mean + SE; * p-value< 0.01. 
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Figure 52: OGT inhibition decreases SREBP-1 expression in MCF7 and SUM-159 
cells (A-B) Quantification of western blot analysis of MCF7 (A) and SUM-159 (B) 
expressing control, OGT#1 and OGT#2 shRNA. Mean + SE; * p-value< 0.05. 
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Figure 53: Essentiality Scores (gene dependency) for OGT correlate with lipogenic 
genes Essentiality scores for breast cancer cell lines presented as a heat map displaying 
OGT essentiality and Pearson correlation and Spearman rank correlations for lipogenic 
and various other genes. Data provided by M. Ivan. 
 
 
104 
 
 
Figure 54: AMPK activity is required for OGT regulation of SREBP-1 (A) 
Quantification of MDA-MB-231 control and OGT shRNA expressing cells treated with 
vehicle control (DMSO) or 10uM Compound C for 24 hours. (B) Western blot analysis 
of MDA-MB-231 cells expressing control or OGT shRNA treated with control vehicle 
(DMSO) or 10uM MG132 for 24 hours analyzed with the indicated antibodies. (C) 
Relative SREBP-1 mRNA expression as measured by qRT-PCR from MDA-MB-231 
cells expressing control, OGT#1, and OGT#2 shRNA. Mean + SE; * p-value< 0.05, ** p-
value< 0.01. 
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Figure 55: OGT inhibition in MDA-MB-231 cells result in AMPK activation and 
phosphorylation of SREBP-1 (A) Cell lysates from MDA-MB-231 cells expressing 
control, OGT-1 or OGT-2 shRNA were analyzed via western blot with the indicated 
antibodies. (B) Western blot analysis of in vitro kinase assay using SREBP-1 protein 
from reticulocyte lysate, ATPγ, and AMPK was immunoprecipitated from control or 
shOGT MDA-MB-231 cells. SREBP-1 nuclear and precursor are indicated by N and P 
markings, IgG heavy chain from immunoprecipitation is marked by IgG. 
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Figure 56: OGT inhibition in MDA-MB-231 cells result in AMPK is required for 
OGT regulation of SREBP-1 and can be blocked through reversing AMPK 
activation in breast cancer cells (A) WT and AMPK -/- MEFs expressing control and 
OGT shRNA were analyzed via western blot with the indicated antibodies. (B) Western 
blot analysis of MDA-MB-231 control cells and shOGT cells treated with vehicle control 
or 10uM methyl pyruvate using the indicated antibodies.  
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Figure 57: AMPK activity is required for OGT regulation of SREBP-1 (A) MDA-
MB-231 cells expressing control and OGT shRNA treated with control vehicle (DMSO) 
or 10uM Compound C for 24 hours were analyzed via western blot with the indicated 
antibodies. (B) Western blot analysis of MDA-MB-157 cells expressing control or OGT 
shRNA treated with control vehicle (DMSO) or 10uM Compound C for 24 hours 
analyzed with the indicated antibodies.  
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Figure 58: FBW7 is elevated by OGT suppression and OGT regulation of SREBP-1 
partly requires GSK3β (A) MDA-MB-231 control and OGT shRNA expressing cell 
lysates were analyzed by western blot using the indicated antibodies. (B) Western blot 
analysis of MDA-MB-231 cells expressing control or OGT shRNA treated with control 
vehicle (DMSO) or 10uM SB216762 for 24 hours analyzed with the indicated antibodies.  
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Figure 59: FBW7- SREBP-1 interaction is increased when OGT is suppressed (A) 
Immunoprecipitation of Fbw7 from MDA-MB-231 control and OGT shRNA expressing 
cell lysates were analyzed by western blot using the indicated antibodies. (B) Western 
blot analysis of immunoprecipitation of FLAG-SREBP-1 from HEK-293T cells 
expressing control or OGT shRNA transfected with FLAG-SREBP-1 were analyzed with 
the indicated antibodies.  
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Figure 60: SREBP-1 restoration rescues  free fatty acids and lipid droplets  (A) 
Relative free fatty acids were quantified after isolation from MDA-MB-231-control or 
MDA-MB-231-SREBP-1 control and OGT shRNA expressing cells.(B) Representative 
fluorescent images of nile red stained cells corresponding to the conditions in (A). Mean 
+ SE; * p-value< 0.05. 
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Figure 61: SREBP-1 restoration rescues expression of FAS and ACLY (A) MDA-
MB-231-control or MDA-MB-231-SREBP-1 control and OGT shRNA expressing cell 
lysates were analyzed by western blot using the indicated antibodies. (B) Quantification 
of western blot analysis of conditions shown in (A). Mean + SE; * p-value< 0.005. **p-
value< 0.001. 
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Figure 62: Cell death induced by OGT suppression is partly rescued after SREBP-1 
restoration (A) Representative images of 2D crystal violet stained and fluorescent 
images of 3D cultured MDA-MB-231-control and MDA-MB-231-SREBP-1 expressing 
control and OGT shRNA. (B) MDA-MB-231-control or MDA-MB-231-SREBP-1 
control and OGT shRNA expressing cell lysates were analyzed with the indicated 
antibodies by western blot.  
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 Figure 63: Soft agar colony assay defects caused by OGT suppression is partly 
rescued after SREBP-1 restoration (A) Representative images of soft agar colony 
forming assays of MDA-MB-231-control and MDA-MB-231-SREBP-1 expressing 
control and OGT shRNA cells cultured for 21 days after fixation and INT staining. (B) 
Quantification of soft agar colonies of MDA-MB-231-control or MDA-MB-231-SREBP-
1 control and OGT shRNA expressing cell. Mean + SE; * p-value< 0.05. 
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Figure 64: SREBP-1 restoration prevents decreases in mTOR signaling that occur 
in response to OGT suppression Western blot analysis of cell lysates from MDA-MB-
231-control and MDA-MB-231-SREBP-1 expressing control and OGT shRNA cells 
using the indicated antibodies. 
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Figure 65: OGT-suppression induced decreases in glycolysis are prevented when 
SREBP-1 expression is restored (A) Glucose consumption calculated from glucose 
measurements from media from cultured MDA-MB-231-control and MDA-MB-231-
SREBP-1 expressing control and OGT shRNA cells for 48 hours. (B) Relative lactate 
was measured after 48 hours from media of cultured MDA-MB-231-control and MDA-
MB-231-SREBP-1 cells expressing control and OGT shRNA. Mean + SE; * p-value< 
0.05, ** p-value< 0.01, *** p-value< 0.001 
116 
 
 
Figure 66: OGT-suppression induced ROS increases, DNA damage and cell stress 
pathway activation is prevented by overexpressing SREBP-1 expression (A) Relative 
intracellular ROS as measured by DCF-DA  staining of MDA-MB-231 cells expressing 
control or SREBP-1 plasmids as well as control or OGT shRNA. (B) Western blot 
analysis of cell lysates from MDA-MB-231-control and MDA-MB-231-SREBP-1 
expressing control and OGT shRNA cells using the indicated antibodies. Mean + SE; * p-
value< 0.01, ** p-value< 0.05,***p-value< 0.001. 
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Figure 67: OGT-suppression induced ER stress in not prevented by restoring 
SREBP-1 expression Western blot analysis of cell lysates from MDA-MB-231-control 
and MDA-MB-231-SREBP-1 expressing control and OGT shRNA cells using the 
indicated antibodies. 
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Figure 68: FAME Analysis shows glucose can be used to synthesize palmitate even 
when OGT is suppressed (A) Fatty Acid Methyl Ester (FAME) Analysis GC-MS 
measurement of unlabelled (m+0) and labelled palmitate isolated from MDA-MB-231 
cells expressing control, OGT#1 and OGT#2 shRNA.  (B) Western blot corresponding to 
cells used in (A). Data provided by J. Lee and K. Wellen. 
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Figure 69: Decreased in vivo tumor growth in response to OGT inhibition is 
prevented when SREBP-1 expression is restored (A) Western blot analysis of cell 
lysates from MDA-MB-231-control and MDA-MB-231-SREBP-1 expressing control and 
OGT shRNA cells using the indicated antibodies. (B) Representative images of IVIS 
bioluminescent imaging as well as tumors removed from Nu/Nu mice injected with cells 
corresponding to the conditions in (A).   
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Figure 70: Decreased in vivo tumor growth in response to OGT inhibition is 
prevented when SREBP-1 expression is restored and model of OGT regulation of 
SREBP-1 (A) Quantification of tumor volume at endpoint using caliper measurements 
from Nu/Nu orthotopic xenograft mice. (B) Model of OGT regulation of SREBP-1 via 
AMPK and SREBP-1 contribution to cancer cell viability. Mean + SE; * p-value< 0.05. 
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 4.4 Discussion 
Cancer cells generate fatty acids via de novo synthesis to support rapid tumor growth and 
survival  [176]. In this study, we demonstrate that O-GlcNAcylation, elevated in nearly 
all cancers [52], acts as a key nutrient sensor to control SREBP expression and lipid 
metabolism in cancer cells. We show that O-GlcNAcylation, via metabolic control of 
AMPK signaling, regulates SREBP-1 phosphorylation and stability and its transcriptional 
targets ACLY and FAS to regulate lipid metabolism and cancer cell growth and survival 
(Figure 70B). Our study uncovers the critical function of O-GlcNAcylation in controlling 
lipid metabolism in tumor cells linking OGT regulation of metabolism to AMPK 
signaling and SREBP regulation. Thus, elevated O-GlcNAcylation not only maintains 
aerobic glycolysis in cancer cells [21], but also maintains lipid metabolism via regulation 
of SREBP independent of OGT regulation of HIF-  
 O-GlcNAcylation has been shown to regulate key transcription factors that 
directly bind to promoters of a number of metabolic enzymes including c-Myc [177], 
HIF- [21] and now SREBP1. These transcription factors allow for coordinate up- and 
down-regulation of entire metabolic processes associated with the Warburg effect in 
cancer cells [178]. c-Myc has been shown to be directly O-GlcNAcylated on threonine 58 
[179] and increase its protein stability. Consistent with these studies, reducing OGT and 
O-GlcNAcylation reduces protein levels of c-Myc. Surprisingly, overexpression of 
SREBP-1 restored c-Myc protein levels in OGT depleted cells suggesting that SREBP-1 
regulation of c-Myc overrides it regulation by O-GlcNAcylation. This, along with 
reversing GLUT1 expression, may explain why overexpression of SREBP-1 partly 
restores glucose and lactate levels in OGT-depleted cells. Importantly, SREBP-1 
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restoration of metabolic defects and mTOR signaling was independent of regulation of 
HIF- -2 can regulate stem cell-like properties in 
prostate cancer cells in part via transcriptional activation of c-Myc [159]. It has also been 
shown that SREBP-1 directly interacts with c-Myc to enhance its transcriptional program 
regulating pluripotency in the context of somatic cells. It is therefore plausible that 
SREBP-1 may regulate c-Myc in other conditions by direct binding or through other 
mechanisms and that SREBP-1 may have broader functions beyond lipid synthesis 
regulation in cancer cells [180]. 
 As noted in the review by Guo et al. [181], regulation of SREBP-1 in cancer 
appears more complex than regulation in non-transformed tissue. With respect to GSK3β 
and FBW7- dependent degradation of SREBP-1, [173, 174] it would be interesting to 
explore how manipulation of OGT affects this mechanism of regulation of SREBP-1 in 
breast cancer, as both GSK3β and its regulator AKT are found to be O-GlcNAc modified 
in different cell types [182, 183]. It is also still unclear if AMPK regulation is through 
increasing SREBP-1 degradation and if these mechanisms are linked. In both non-
transformed and cancer tissue SCAP appears to play an important role in SREBP-1 
regulation. It was recently demonstrated that N-glycosylation of SCAP (in response to 
increasing glucose) regulated the interaction between SCAP and Insig-1 and therefore 
SREBP-1 activation in tumor cells [184]. Our studies suggest that in breast cancer cells 
and MEFs, nutrient sensor O-GlcNAcylation can regulate SREBP-1 protein levels and its 
transcriptional targets via regulation of AMPK. 
 Although the requirement of lipogenesis has been well chronicled in a variety of 
cancer tissues, inhibition of this process as a means of therapy has proved challenging. 
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Much focus has been concentrated on factors upstream of SREBP-1 such as EGFR, 
mTOR and P13K [181] however FAS and ACLY inhibitors do exist. Genetic inhibition 
of lipogenesis downstream of SREBP-1 favors the use of inhibitors against enzymes such 
as FAS and ACLY for the treatment of cancer. Compounds targeting FAS such as 
cerulenin, C75 and orlistat demonstrated effective inhibition of cancer cell 
growth/survival but resulted in unintended consequences of decreased food intake and 
body weight in animal studies which ultimately halted their prospects as potential cancer 
therapeutics [112]. More recently, the FAS inhibitor TVB-2640, which carries a more 
favorable tolerability [185], entered phase I clinical trials for solid malignant tumors 
[176]. We propose that OGT inhibition may be a way to provide anti-tumor effects, via 
reduction of lipogenic enzymes.  
 As OGT and O-GlcNAc play a role in other pathologies, such as atherosclerosis 
and diabetes, the regulation of SREBP-1 may be important in these contexts as well. 
Work by Li et. Al demonstrated that AMPK regulates SREBP-1 in diet-induced insulin 
resistant mice and activation of AMPK to inhibit SREBP-1 protects these animals from 
hepatic steatosis, hyperlipidemia, and accelerated atherosclerosis in these conditions 
[158]. AMPKα and γ are both known to be directly O-GlcNAcylated [186] and OGT is 
known to be phosphorylated by AMPK implying intensive cross-talk between nutrient 
sensitive regulatory mechanisms of cellular behavior. AMPK activation by OGT in breast 
cancer may be in response to changes in metabolism such as glucose uptake, rather than 
direct O-GlcNAcylation changes as our data shows that restoring nutrients that support 
bioenergetics, in the context of OGT suppression, reverses this activation. Interestingly, 
direct O-GlcNAc modification was previously found to occur on and regulate 
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Carbohydrate-responsive Element Binding Protein (ChREBP) and Liver X Receptor 
(LXR), both important transcriptional regulators of lipid metabolism in the liver [170, 
187]. The O-GlcNAcylation status of these factors in cancer and their relation to lipid 
synthesis have yet to be explored but are of interest since in hepatocytes these factors 
reinforce lipogenic signaling through SREBP-1 and each other [188]. 
 Together this work links OGT and O-GlcNAcylation to direct regulation of lipid 
metabolism, a process critical for cancer cell growth and survival. The detrimental 
consequences to cancer cell health imparted through inhibition of lipogenesis via genetic 
or pharmacological means have been demonstrated in vitro, however clinical efforts have 
not met initial hopes [189]. Targeting OGT in cancer may serve as a therapeutic 
alternative to directly targeting enzymes such as FAS or ACLY in not only breast cancer 
but in other cancers as well.   
CHAPTER 5: OGT REGULATES LIPID LEVELS AND LIPOGENIC GENES IN 
LACTATION 
5.1 Introduction 
5.1.1 Introduction to and development of the mammary gland  
The mammary gland is an incredibly complex secretory organ due to its composition 
consisting of multiple cell types, its role as the distinguishing factor defining mammals, 
and its development into adulthood which differs from other organs [190]. The mammary 
gland functions to provide nourishment to newborns as it develops not only in utero, and 
puberty, but also undergoes immense developmental and physiological changes in 
adulthood during pregnancy to achieve nutrient production in response to altered 
125 
 
hormonal cues. Regulation of mammary gland development in puberty and adulthood 
differs from that in embryogenesis in that in utero signals that dictate developmental 
changes originate from the mesenchyme [191]. In puberty and adulthood, hormonal 
regulation causes differentiation to generate alveoli (structures capable of secreting milk 
during lactation). When the demand for milk subsides, the process of involution 
commences during which time remodeling occurs to the mammary gland returning it to a 
state similar to physiology prior to pregnancy [191].  Careful and deliberate coordination 
of many signals is required for proper changes within the mammary gland.  
Development of the mammary gland has been well described and begins in utero with the 
generation of rudimentary ductal structures that subsequently become bulbs of epithelial 
cells developing from placodes which are ectoderm structures [190]. Both elongation 
from the terminal end bud and ductal branching occur after birth, mainly during and after 
puberty [192]. The terminal end bud is a structure at the tip of growing ducts and drives 
ductal growth through proliferation. Tree-like ductal arrangement occurs as secondary 
ductal branches fill more than half of the stroma [191]. The remaining space can be filled 
by continuous secondary and tertiary ductal growth and alveolar buds that occur during 
pregnancy. During pregnancy, the mammary epithelium, comprised of both basal and 
luminal cells, expand into the fat pad from the nipple. The fat pad contains not only 
adipocytes but also endothelial cells and immune cells [191]. The small population of 
stem cells, capable of differentiating to different cell types in the mammary gland, exists 
as basal myoepithelial lineage-restricted cells [193]. Basal myoepithelial cells also 
generate the outer layer of the gland which contracts to release milk. Both ducts and 
alveolar structures, which secrete milk, are generated by luminal epithelial cells (Figure 
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71A) [191]. It is important to note that proliferation and apoptosis of epithelial cells 
occurs in the mammary gland during each estrus cycle but the sequence of events that 
occurs during pregnancy is much more rapid, dramatic and sustained [190, 191]. As the 
epithelilal compartment spreads, existing adipose is diluted [194]. The luminal epithelial 
cells generate and release milk proteins into the alveoli where milk is pushed through the 
ducts towards the nipple by contraction [190]. In mid-pregnancy, massive proliferation 
generates more and larger epithelial cells and secretory activation is initiated. Complete 
lobuloaveoular differentiation (generating a circular lumen surrounded by a single layer 
of polarized alveolar epithelial cells encased by myoepithelial cells) is denoted by the 
formation of lipid droplets and particular gene expression changes. Milk and proteins 
enter the lumen in preparation of secretion as the female and offspring near parturition 
[195].  
5.1.2 Signaling that regulates mammary gland development  
Signaling mechanisms originating both locally (from regions such as the surrounding 
ECM) as well as from other organs (such as the ovary) dictate the changes that mark 
progression through stages of pregnancy and lactation [194, 196]. Early in pregnancy, 
both progesterone and prolactin (PRL) initiate remarkable proliferation. Wnt4 and Nf-KB 
are thought to mediate the effects of PRL, in concert with JAK2/Stat5 which are activated 
directly by PRL receptor [196]. ErbB4 signaling receptor (EGFR family member) 
cooperatively actives Stat5 [195, 197]. All of these signaling alterations act to drive 
proliferation, establish polarity, coordinate cell-cell interactions and regulate the 
production of proteins during alveolar morphogenesis.  Expression of glucose and 
nutrient transporters is imperative for the procurement of building blocks that contribute 
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to the production of main milk components including lactose, protein and lipids. Glucose 
transporter GLUT1, sodium/glucose transporter Slc5a1, amino acid transporters Slc7a5 
and Slc1a4, and the fatty acid transporter Slc27a3 are all upregulated at the transcript 
level between 1.25 and 2.9 fold at the onset of lactation [194].  
It has been noted that tissue remodeling and morphological and signaling mechanisms 
that occur during mammary gland development are also pertinent in cancer biology as 
many of these same pathway changes are mimicked as they become deregulated and 
dysfunctional in disease [192].  One such biological process that is deregulated in cancer 
and active in mammary development (specifically lactation) is lipid synthesis. 
5.1.3 Lipids and lipogenic genes in lactation 
As stated previously, most normal tissue do not need de novo lipogenesis or expression of 
lipogenic enzymes because their requirement for fatty acids is met by utilization of those 
circulating in the blood stream derived from the diet. One exception to this is the lactating 
mammary gland which does activate lipid synthetic genes and produce lipids.  During 
pregnancy, it has been determined that adipocytes contained in the fat pad decrease their 
lipid content which implies that they serve as a reserve to donate to lipid content in milk 
[190], however it has also been found that de novo lipogenesis increases to generate 
lipids, which along with proteins, provides nutrients to offspring, with fat percentage of 
milk ~30% [194]. In this context, lipids contribute high-energy metabolites necessary for 
lipid membranes, ATP generation and the synthesis of myelin needed for proper brain 
development [194]. SREBF1 transcript increases in early lactation as compared to 
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expression in late pregnancy and SREBP1c -/- mice have lactation defects demonstrating 
the importance of lipid synthesis in lactation [194].  
Expression of lipogenic genes was found to significantly increase from late pregnancy to 
early lactation. Rudolph et. Al compared mammary glands from pregnant mice at day 
P17 (late pregnancy) and L2 (early lactation) examining expression of a large panel of 
metabolic genes. They noted an increase in many glycolytic genes  such as; glucose 
transporters, glucose-6-phosphate dehydrogenase 2, pyruvate kinase (muscle) (PKM2), 
lactate dehydrogenase (LDHA), This correlated with a decrease in several TCA genes, 
changes which parallel those associated with cancer cells metabolism compared to 
normal (termed the Warburg effect which was outlined in Chapter 1) [194]. They also 
found that in early lactation, alpha-lactalalbumin (a gene regulated by the Stat5 
transcription factor) was upregulated nearly 15 fold [194, 198]. The changes in glycolytic 
genes could provide substrates for use in the synthesis of fatty acids. They noted that 
genes required for de novo fatty acid synthesis and triglyceride synthesis were also 
upregulated significantly in early lactation compared to late pregnancy. This included 
ACLY, FASN, ELOVL1, Malic enzyme (Mod1), Stearyl-CoA desaturase 1/2 (Scd1 and 
Scd2, and Long-chain Acyl CoA synthetase 1 (Acsl1). While OGT has roles in 
development, its contribution to mammary development and processes associated with 
pregnancy had yet to be examined (with the exception of placental studies mentioned in 
Chapter 1).  
  
5.2 Results 
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5.2.1 O-GlcNAcylation regulates lipogenesis in lactation in vivo  
We examined the role of OGT in the regulation of de novo lipogenesis in a non-
cancerous in vivo tissue system. The lactating (murine) mammary gland is one of the 
most active lipid synthesizing organs known as it produces an estimated 32 grams of 
triacylglycerides (TAG) over a 20 day lactation period, a mass similar to murine body 
weight [192, 194]. While multiple regulatory layers exist and several substrates are used 
to synthesize TAG, a crucial source is de novo synthesized lipids [194]. In support of the 
role of lipogenic genes in the production of lipids in milk, it has been demonstrated that 
SREBP-1 and many of its transcriptional targets are upregulated at secretory activation 
[194].  To determine if OGT regulates SREBP-1 or de novo lipogenesis in lactation, we 
manipulated OGT expression in B6.129-Ogttm1Gwh/J OGT floxed Cre mice at various 
stages of lactation. The first experimental design (Figure 71B) was the deletion of ogt at 
weaning. Female B6.129-Ogttm1Gwh/J OGT floxed Cre mice were bred to generate 
offspring and we established that the female B6.129-Ogttm1Gwh/J OGT floxed Cre was 
capable of feeding pups after their birth. We allowed the female mice to nurse their litters 
until weaning at which point they were injected for three days once daily with adenoviral-
GFP (Ad-GFP) as control or adenoviral-Cre recombinase (Ad-Cre) to delete ogt in the 
inguinal fat pad. We assessed the delivery of adenovirus to the mammary fat pad using 
the Ad-GFP fat pad after collection and determined that we achieved delivery to 
approximately 60% of the tissue [199]. It was evident from western blotting that OGT 
expression was still detectable in Ad-Cre sample however it was sufficiently decreased. 
Immunohistochemical (IHC) analysis of mammary fat pads also revealed a dramatic 
decrease in OGT expression in the Ad-Cre sample compared to Ad-GFP control (Figure 
130 
 
74A, 76A, 77A).  Histological staining confirmed that mammary glands of the pregnant 
females contained many more milk secreting cells compared to control virgin B6.129-
Ogttm1Gwh/J OGT floxed Cre mice. There were substantial morphological changes 
present when ogt was deleted as determined by H&E staining (Figure 74A). When 
examining lipogenesis, both lipid droplet content as well as SREBP-1 and FAS 
expression were decreased as a result of ogt deletion (Figure 74A). 
We also examined B6.129-Ogttm1Gwh/J OGT floxed Cre female non-lactating 
mammary tissue by injecting control (Ad-GFP) and Ad-Cre to knockout ogt and then 
collected mammary fat pads for examination of expression of lipogenic enzymes. We 
found that even in normal non-lactating tissue ogt deletion resulted in decreased 
expression of SREBP-1 and FAS (Figure 72A, 73A). However, there were negligible 
effects on lipid droplet content when ogt was deleted indicating that the expression of 
these enzymes may not affect lipid levels in non-lactating tissue (Figure 73B). Since 
expression of lipogenic enzymes is reported to be minimal as lipid synthesis is not an 
active process under these conditions [141] changes in levels of protein that are present 
may not result in biological consequences and may therefore have little meaning.  
We examined the role of OGT on factors in lactation by deleting ogt at the beginning of 
lactation. Post-parturition, adenoviral Cre or adenoviral GFP was injected into the fat 
pads of the B6.129-Ogttm1Gwh/J OGT floxed Cre females daily for three days starting 
on the day of litter birth. After which point, offspring were allowed to feed ad lib for 21 
days then weaned, at which point female B6.129-Ogttm1Gwh/J OGT floxed Cre mouse 
mammary fat pads were harvested (Figure 75).  We confirmed knockout by western blot 
and IHC (Figure 76A, 77A) and observed that deletion of ogt in the mammary fat pad 
131 
 
decreased lipid droplets as measured by nile red staining (Figure 76A) and the amount of 
milk secreting cells (Figure 76A). Pups were weighted at various points throughout 
lactation as weight has previously been used as a proxy for nutrient content delivered, 
specifically lipid content [200]. Pups suckled from ogt knockout mice had significantly 
reduced average litter weight compared to control (Ad-GFP) fed pups (Figure 78A). 
Compared litters contained the same number of offspring. Consistent with decreased lipid 
droplets, we also noted a decrease in SREBP-1 and FAS protein expression upon ogt 
deletion as measured by western blot analysis and IHC (Figures 76A, 77A), confirming 
the requirement of OGT in lipogenenic enzyme expression associated with lactation. 
Changes in IHC H&E staining shown upon ogt deletion are similar to those seen upon 
Src deletion which could mean that ogt deletion accelerates involution. Accelerated 
involution phenotypes during lactation observed when Src was deleted was hypothesized 
to be a result of decreased secretory activation [201].  Not only did we observe decreases 
in expression of lipogenic genes when ogt was deleted in early lactation, but many 
signaling regulators required for proper lactogenesis and maintenance of lactation were 
also decreased. When compared to control dams (Ad-GFP), OGT null (Ad-Cre) 
expressed less total ErbB2, ErbB3, and ErbB4 (all EGFR family members) (Figure77A). 
Casein protein expression was dramatically decreased when ogt was deleted in the 
lactating mammary gland, which in concert with decreased lipid droplets, could 
contribute to reduced caloric content and therefore pup weight (Figure77A).    
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5.3 Figures and Figure Legends 
 
 
Figure 71: Mammary fat pad development and experimental design of OGT 
deletion in mammary fat pads (A) Mammary fad pad development through pregnancy 
consists of six stages. Outgrowth of ducts begins at the nipple and continues into 
secondary branching structures capped by terminal end buds. Many signaling factors 
influence and regulate the proper biological changes required for lactation. When 
lactation is complete involution and apoptosis of structures occurs. LYND indicated 
lymph node. (B) Schematic of experimental procedures of deletion of ogt at different 
time points indicated by red stars. These included time points at weaning (end of 
lactation), and parturition (birth of litter). 
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Figure 72: Deletion of OGT in non-lactating B6.Ogt-loxP/loxP female mice 
mammary fat pads decreases expression of SREBP-1 and FAS Western blot analysis 
of lysate extracted from mammary fat pads of B6.Ogt-loxP/loxP female mice injected 
with adenoviral-GFP or adenoviral-Cre recombinase using the indicated antibodies.   
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Figure 73: Deletion of OGT in non-lactating B6.Ogt-loxP/loxP female mice 
mammary fat pads decreases expression of SREBP-1 (A) Quantification of SREBP-1 
from western blot analysis of lysate extracted from mammary fat pads of B6.Ogt-
loxP/loxP female mice injected with adenoviral-GFP or adenoviral-Cre recombinase 
using the indicated antibodies. (B) Nile red staining of fat pads removed from Ad-GFP 
and Ad-Cre injected B6.Ogt-loxP/loxP female mouse mammary fat pads. Mean + SE; * 
p-value< 0.001. 
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Figure 74: Deletion of OGT in Lactating B6.Ogt-loxP/loxP female mice mammary 
fat pads decreases lipid droplets and expression of SREBP-1 and FAS 
Immunohistochemistry staining of mammary fat tissue from lactating and non-lactating 
B6.Ogt-loxP/loxP female mice  injected with Ad-GFP or Ad-Cre at weaning (21 days 
after parturition for lactating mice). 
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Figure 75: Schematic for experimental assessment of pup weight as proxy of 
nutritional delivery in Ad-GFP (control) and Ad-Cre (OGT k/o) mammary fat pads 
injected at parturition B6.Ogt-loxP/loxP female mice were injected with Ad-GFP or 
Ad-Cre at parturition (pup birth) for three days. Weight of litters were recorded until 
weening (~3 weeks after birth). Mammary fat pads were collected from adult females at 
weaning and IHC was performed. 
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Figure 76: Deletion of OGT in lactating B6.Ogt-loxP/loxP female mice mammary fat 
pads decreases lipid droplets, lactocytes and expression of SREBP-1 and FAS 
Immunohistochemistry staining of mammary fat tissue from lactating and non-lactating 
B6.Ogt-loxP/loxP female mice  injected with Ad-GFP or Ad-Cre parturition and collected 
at weaning.  
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Figure 77: Deletion of OGT in lactating B6.Ogt-loxP/loxP female mice mammary fat 
pads decreases expression of lipogenic genes, receptors, milk protein casein and 
developmental genes. Western blot analysis of lysate extracted from mammary fat pads 
of B6.Ogt-loxP/loxP female mice injected with adenoviral-GFP or adenoviral-Cre 
recombinase at parturition using the indicated antibodies.  
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Figure 78: Deletion of OGT in lactating B6.Ogt-loxP/loxP female mice mammary fat 
pads decreases pup litter weight. (A) Total weight of litters (each containing 9 pups) 
fed from Ad-GFP control injected or Ad-Cre injected dams for 21 days. One-Way 
ANCOVA comparison *p<0.05 (B) Model by which OGT could regulate expression of 
key factors required in lactogenesis.  
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5.4 Discussion 
It is clear from this data that OGT is playing an important role in proper expression of 
several factors needed for the production of nutrients during lactation. This is evident by 
OGT-suppression induced decreases in expression of signaling receptors such as the 
EGFR family members examined, β Casein which serves as milk protein and lipogenic 
enzymes such as ACLY and FAS and their upstream regulator SREBP-1 transcription 
factor (Figure 77A). This conclusion can also be drawn due to the decreased pup weight 
in litters containing the same number of pups when fed from dams where ogt has been 
deleted compared to control (Figure 78A). It is unclear if the decrease in pup weight is 
due to decreased production of lipids which contributes to milk calories. It is very likely a 
consequence of a variety of changes that occur in response to ogt deletion including 
decreased expression of factors required for lipogenesis as well as the decreased 
production of milk protein (Casein). Casein is regulated through factors in the EGFR 
family (shown here to decrease upon ogt deletion in lactation) as well as other factors that 
we have not examined including STAT5 (Figure 78B). It is also possible that the 
decrease in HIF1α upon ogt deletion may lead to decreased uptake of glucose required 
for lipogenesis through the glucose transporter GLUT1. It is of interest to determine if 
lipids in milk are decreased by the changes we observe in SREBP-1, FAS and ACLY, as 
here we have only demonstrated that within the mammary fat pad itself, rather than in 
milk, there is a decrease in lipid droplets (contain triglycerides made from FFA). We 
have also observed morphological changes by H&E stain that appear similar to the 
accelerated involution during lactation observed in Src -/- lactating dams [201]. In that 
manuscript, it was concluded that this enhanced involution phenotype resulted from a 
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failure of secretory activation. In the case of ogt deletion, further experimental aims are 
required to distinguish between blocked differentiation or another possibility which is the 
induction of cell death.  
CHAPTER 6: METHODS 
Metabolite Analysis 
MDA-MB-231 cells were cultured and stably infected with control or OGT shRNA for 
48 hours as described above. Cells were counted, and approximately 107 cells per sample 
were spun down at 300g for 3 min in a polystyrene tube. Cells were washed twice with 
PBS and then snap-frozen on dry ice and stored at −80 °C until analysis by Metabolon 
(Durham, NC). The untargeted metabolic profiling platform employed for this analysis 
combined three independent platforms:  ultrahigh performance liquid 
chromatography/tandem mass spectrometry (UHLC/MS/MS
2
) optimized for basic 
species, UHLC/MS/MS
2
 optimized for acidic species, and gas chromatography/mass 
spectrometry (GC/MS).  Cells were homogenized in a minimum volume of water and 
100μL withdrawn for subsequent analyses.  Using an automated liquid handler (Hamilton 
LabStar, Salt Lake City, UT), protein was precipitated from the homogenized cells with 
methanol that contained four standards to report on extraction efficiency.  The resulting 
supernatant was split into equal aliquots for analysis on the three platforms as described 
previously [202, 203].  Aliquots, dried under nitrogen and vacuum-desiccated, were 
subsequently either reconstituted in 50μL 0.1% formic acid in water (acidic conditions) 
or in 50μL 6.5mM ammonium bicarbonate in water, pH 8 (basic conditions) for the two 
UHLC/MS/MS
2
 analyses or derivatized to a final volume of 50μL for GC/MS analysis 
using equal parts bistrimethyl-silyl-trifluoroacetamide and solvent mixture 
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acetonitrile:dichloromethane:cyclohexane (5:4:1) with 5% triethylamine at 60°C for one 
hour.  In addition, three types of controls were analyzed in concert with the experimental 
samples: samples generated from pooled experimental samples served as technical 
replicates throughout the data set, extracted water samples served as process blanks, and 
a cocktail of standards spiked into every analyzed sample allowed instrument 
performance monitoring. For UHLC/MS/MS
2
 analysis, aliquots were separated using a 
Waters Acquity UPLC (Waters, Millford, MA) and analyzed using an LTQ mass 
spectrometer (Thermo Fisher Scientific, Inc., Waltham, MA) that consisted of an 
electrospray ionization (ESI) source and linear ion-trap (LIT) mass analyzer.  The MS 
instrument scanned 99-1000 m/z and alternated between MS and MS
2
 scans using 
dynamic exclusion with approximately 6 scans per second.  Derivatized samples for 
GC/MS were separated on a 5% phenyldimethyl silicone column with helium as the 
carrier gas and a temperature ramp from 60°C to 340°C and then analyzed on a Thermo-
Finnigan Trace DSQ MS (Thermo Fisher Scientific, Inc.) operated at unit mass resolving 
power with electron impact ionization and a 50-750 atomic mass unit scan range. 
Metabolites were identified by automated comparison of the ion features in the 
experimental samples to a reference library of chemical standard entries that included 
retention time, molecular weight (m/z), preferred adducts, and in-source fragments as 
well as associated MS spectra and curated by visual inspection for quality control using 
software previously described [204]. Experimental samples and controls were 
randomized across a one-day platform run.  Any missing values were assumed to be 
below the limits of detection and for statistical analyses and data display purposes, these 
values were imputed with the compound minimum (minimum value imputation) after 
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normalization to total protein for each sample.  Statistical analysis of log-transformed 
data was performed using Array Studio software (Omicsoft, Inc) and R (http://cran.r-
project.org/).  Welch’s t-tests were performed to compare data between experimental 
groups.  Multiple comparisons were accounted for by estimating the false discovery rate 
(FDR) using q-values. 
Tissue Culture 
MCF-10A, SKBR-3, BT474, MDA-MB-231 and MCF-7 cells were purchased from 
ATCC and cultured following instructions. MDA-MB-231 cells stably overexpressing 
plko.FLAG-SREBP1 (Addgene- plasmid 32017 from Dr. D Sabatini) and MCF7-FLAG--
OGT cells were generated through production of lentivirus. Control-scrambled 
CCTAAGGTTAAGTCGCCCTCGCTCTAGCGA GGGCGACTTAACCTT (Addgene, 
Cambridge, MA, USA), c-Myc#1 
CCGGCAGGAACTATGACCTCGACTACTCGAGTAGTCGAGGTCATAGTTCCTG
TTTTTG, c-Myc#2 
CCGGCAGGAACTATGACCTCGACTACTCGAGTAGTCGAGGTCATAGTTCCTG
TTTTTG, HSP90 #1 
CCGGGAAGGATGGTGACAAGAAGAACTCGAGTTCTTCTTGTCACCA 
TCCTTCTTTTTG, HSP90#2 CCGGTATGGCATGACAACTACTTTACTCGAGTAA 
AGTAGTTGTCATGCCATATTTTG (Sigma Aldrich, St. Louis, MO, USA).  
OGT knockdown was achieved using two different lentiviral constructs. OGT shRNA 
constructs were acquired from Sigma and the sequences used for OGT-1: 
GCCCTAAGTTTGAGTCCAAATCTCGAGATTTGGACTCAAACTTAGGGC and for 
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OGT-2: 
GCTGAGCAGTATTCCGAGAAACTCGAGTTTCTCGGAATACTGCTCAGC. 
Control shRNA was acquired through Addgene (plasmid 1864), from D. Sabatini 
(Whitehead Institute for Biomedical Research, MIT) and the sequence used was: 
CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG. 
pLKO-Puro vectors carrying control (scramble sequence) shRNA, c-MYC shRNA (c-
MYC#1 and c-MYC#2 shRNA sequences), HSP90 shRNA (HSP90#1 and HSP90#2 
shRNA sequences) and OGT shRNA sequences (OGT-1 or OGT-2) shRNA were 
packaged into VSVG-pseudotyped lentiviruses, through co-transfection of HEK-293T 
packaging cells with 10 µg of vector DNA and appropriate packaging vectors. Viral 
production was carried out as previously described [59]. SUM-159 cells were a generous 
gift of T. Seagroves. WT and AMPKα1/α2 KO MEFs were kindly provided by B Viollet 
(INSERM) and cultured as previously described [157].Wild type and TSC2-/- MEFS 
were a gift from Aristotelis Astreinidis, Drexel University College of Medicine. 
CommaD cells were a gift from Senthil Muthuswamy, University of Toronto. MCF-10A-
ErbB2 (NeuT) [59], MCF-10A-AKT (Myr-AKT1) [205] and MCF-10A-MEK2 (MEK2-
DD) [205] cells have been previously described. The pWZL-Blast-c-MYC plasmid 
(kindly provided by Michael Amatangelo, Drexel University) was used to make MCF-
10A cells stably overexpressing c-MYC (MCF-10A-c-MYC). Cells were infected with 
retrovirus and selected as previously described [59]. 
Establishing MMTV-Myc cells 
MMTV-c-Myc transgenic females were procured from the Mouse Models of Human 
Cancer Consortium (MMHCC; stock O1XG2) under protocols approved by the 
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University of Tennessee Health Science Center. Mammary epithelial tumor cell (MTEC) 
lines were generated from late stage carcinomas, grown in DMEM/F12 + 2% FBS and 
then routinely passaged in culture using a 3:1 ratio of dispaseII/tryspin as previously 
described [206]. This cell line was established by Dr. Tiffany Seagroves with technical 
support from Raisa Krutilina and Luciana P. Schwab.  
Western blotting  
Western blotting procedures were carried out as previously described [59]. Briefly, Cells 
were collected in RIPA lysis buffer (150mM NaCl, 1% NP40, 0.5% DOC, 50mM Tris-
HCl at pH 8, 0.1% SDS, 10% glycerol, 5mM EDTA, 20mM NaF and 1mM Na3VO4, 1 
µg/ml each of pepstatin, leupeptin, and aprotinin, 200 µg/ml phenyl-methylsulfonyl-
fluoride).  Lysates were cleared by centrifugation at 14,000 x g for 20 minutes at 4 
o
C and 
analyzed by SDS-PAGE and autoradiography.  Antibodies were purchased from the 
following companies; Anti-SREBP1 (Novus Biologicals, Abcam), Anti-OGT (Sigma, 
Santa Cruz), Anti-O-GlcNAc (Santa Cruz, Sigma), Anti-FAS (Cell Signaling), Anti-
ACLY (abcam), Anti-phospho-SREBP1 (S372) (Cell Signaling), Anti-phospho-AMPK 
(T172) (Cell Signaling), Anti-AMPK (Cell Signaling), Anti-FLAG (Sigma), Anti-
Cleaved Caspase 3 (Cell Signaling), Anti-Actin (Santa Cruz),  Anti- Cleaved PARP (Cell 
Signaling), Anti-Bcl2 (Santa Cruz), Anti-Glut1 (Abcam), Anti-Hif1α (Novus 
Biologicals), Anti-ACC (Cell Signaling) Anti-phospho-Raptor (S792) (Cell Signaling), 
Anti-Raptor (Cell Signaling), Anti-c-MYC (Novus Biologicals), Anti-S6 Ribosomal 
protein (Cell Signaling), Anti-phospho-S6 Ribosomal Protein (S240/244) (Cell 
Signaling), Anti-4EBP1 (Cell Signaling), Anti-phsopho-4EBP1 (T70) (Cell Signaling), 
Anti-c-MYC (Santa Cruz), Anti-ERK2 (D-2) (Santa Cruz), Anti-Cyclin D1 (Santa Cruz), 
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Anti-phospho-Akt (Ser473) (Cell Signaling), Anti-phospho-Akt (T308) (Cell Signaling), 
Anti- P70 S6 Kinase (Cell Signaling), Anti-Tuberin/TSC2 (Cell Signaling), Anti-AKT 
(Cell Signaling), Anti-phospho-P70-S6 Kinase (T389) (Cell Signaling),  Anti-phospho-
4EBP1 (T70) (Cell Signaling), Anti-4EBP1 (53H17) (Cell Signaling), Anti-BIM (Cell 
Signaling), Anti-CHOP (L63F7) (Cell Signaling), Anti-phospho-eIF2α (Cell Signaling), 
Anti-eIF2α  (Cell Signaling), Anti-phospho-ERK (T185/Y187) (Invitrogen Corporation), 
Anti-O-GlcNAc (CTD110.6) (Sigma), Anti-HSP90 alpha (Enzo Life Sciences), Anti-
MGEA5 (OGA) (Proteintech Group) Anti-γH2A.X (S139) (Abcam), Anti-H2A.X (Cell 
Signaling), Anti-P38 (Cell Signaling), Anti-phospho-P38 (T180/Y182) (Cell Signaling). 
Densitometry was performed using Image J Software (National Institutes of Health, 
Bethesda, MA).  
Immunoprecipitation  
MDA-MB-231 cells expressing control or OGT shRNA or HEK-293T cells transfected 
with human-SREBP-1c were lysed and extracted with radioimmune precipitation assay 
buffer (RIPA) (150 mM NaCl, 1% NP40, 0.5% DOC, 50 mM TrisHCL at pH 8, 0.1% 
SDS, 10% glycerol, 5 mM EDTA, 20 mM NaF, and 1 mM Na3VO4) supplemented with 
1 μg/ml each of pepstatin, leupeptin, aprotinin, and 200 μg/ml PMSF. Protein G 
Sepharose beads were pre-cleared Lysates were incubated with indicated antibodies 
overnight at 4 degrees C. Samples were then subjected to immunoprecipitation using 
protein G Sepharose beads followed by 3x washes in 1x phosphate buffered saline + 
0.1% Tween 20. Immunoprecipitated proteins were suspended in 5x protein buffer and 
boiled for 5 minutes at 100 degrees C then centrifuged prior to western blot analysis 
using the indicated antibodies.  
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Free Fatty Acid Quantification 
Free Fatty Acids were isolated and quantified using the Fatty Acid Kit from Biovision as 
per the manufacturers’ instructions. Briefly, cells were counted and equal numbers from 
each sample were used for quantification. Lipids were isolated using a choloform/1% 
Triton X solution and needle lysing. Cells were centrifuged and the lipid containing layer 
was dried. Lipids were resuspended and acyl-CoA derivatives were generated using a kit 
provided enzyme. Colormetric detection of lipids was performed in a Synergy HT plate 
reader (BIO-TEK Instruments Inc.) at 570 nm. Spectrometric numbers were plotted 
against a standard and data was normalized to control and presented graphically.  
Nile Red Staining of Cells and Tissue 
Cells were fixed using 4% Formalin and washed in 1xPBS prior to staining. Stock 
solution of 0.5mg/ml was made in acetone and diluted to 5ug/ml in PBS for use. Working 
solution was gently added to cells and incubated for 30 minutes away from light. Cells 
were then washed three times in 1x PBS and visualized and photographed on EVOS FL 
(Life technologies) using Texas Red filter.  
Inhibitors and treatments 
Cell were seeded at 5 x 10
6
 were treated for 16 hours with either; 0.1% DMSO (Sigma, 
St. Louis, MO, USA), LY294002 30 µM (Promega WI, USA), Rapamycin 50 nM (Enzo 
Biochem NY, USA) or U0126 30 µM (Promega WI, USA). OGT inhibitor Ac-
5SGlcNAc has been previously described [76] and HSP90 inhibitor 17-AAG (Selleck 
Biochem, Houston, TX, USA) was used at indicated concentrations. Lactacystin 
(Calibiochem, Billerica, MA,USA) was used at 10 µM in combination with indicated 
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treatments. SB216763 (Sigma, St. Louis, MO, USA) was used at a concentration of 
10µM for 6 hours. Cells were treated with 10µM Compound C (Calbiochem), 10µM 
methyl pyruvate, or 10µM MG132 for 24 hours. Ac-5s-GlcNAc was added to plated cells 
at a concentration of 100µM (unless indicated at other concentration) for either 24 or 48 
hours as indicated. Exogenous lipids consisted of 1%BSA/PBS100µM sodium palmitate 
and 40µM oleic acid and were added to media on plated cells for 48 hours.  
in vitro kinase assay  
In-vitro kinase assay SREBP-1 protein was generated using TNT-T7 Quick Coupled 
Transcription/Translation System (Promega) and the human-FLAG-SREBP-1c plasmid, 
following manufacturers’ instructions, was incubated with 20 l of Protein-G Agarose 
beads after immunoprecipitation of AMPKα from MDA-MB-231 control or MDA-MB-
231 shOGT cell lysates in kinase buffer (50 mM HEPES [pH 7.5], 0.65 mM MgCl2, 0.65 
mM MnCl2, 12.5 mM NaCl) with 500 M ATPS. Kinase reactions were then incubated 
at 30C for 30 minutes. When appropriate, PNBM (dissolved in DMSO) was added at 2.5 
mM, and reactions were incubated at room temperature for one hour followed by the 
addition of 4X protein sample buffer and reactions were boiled for five minutes. Western 
bloat analysis was used to analyze reactions using the indicated antibodies. 
mRNA expression 
RNA was isolated from cells using Qiagen RNEasy products and protocols (Qiagen, 
Valencia, CA, USA). Taqman gene expression assay primer probes for primer probes for 
OGT (Hs00914634_g1), c-MYC (Hs00905030_m1), HSP90AA1 (Hs00743767_sH), 
SREBF-1 (Hs1088691-m1), ACLY (Hs00982738-m1), FASN (Hs0105622-m1), 
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ACACA (Hs01046047-m1), ELOVL7 (Hs00405151-m1), LPL (Hs00173425-m1) and 
Cyclophilin A (PPIA) (Hs99999904_m1) were purchased from Applied Biosystems 
(Foster City, CA, USA). qRT-PCR was performed as previously described [207] using 
Brilliant II qRT-PCR Master Mix 2 Kit (Stratagene) using Applied Biosystems 7500 
machine according to the manufacturer’s protocols. Expression levels were analyzed 
using Data Assist v2.0 (Life Technologies, Grand Island, NY, USA).  
Animal experiments 
Athymic nude Nu/Nu 5-6 week old female mice (Charles River, Wilmington, MA, USA) 
were anesthetized with 4% isoflurane and inoculated with 1.5 x 10
6
 MDA-MB-231 cells 
stably expressing luciferase and either pBabe-Control or plko-SREBP-1c as well as either 
Control or OGT shRNA. Cells were injected in 100 µl of 1x PBS containing 20% 
matrigel (Invitrogen) using a 271/2-gauge needle into the fourth inguinal mammary fat 
pad. For bioluminescence imaging, mice were injected intraperitoneally with 200 µl of 
D-luciferin solution (9 mg/ml; Caliper Life Sciences, Hopkinton, MA). Imaging was 
completed using IVIS 200 imaging system 3 hours after the mammary fat pad injection to 
detect the distribution of breast cancer cells as well as weekly to monitor tumor growth 
and results were analyzed using Living Image software (Caliper Life Sciences). Tumors 
were measured weekly using digital calipers (Fowler Co., Inc., Newton, MA, USA) along 
and perpendicular to the longest dimension. Tumor volumes were calculated as 
V=(length)x(width)2 x0.52. At endpoint tumors were excised. All protocols involving the 
use of animals were approved by the Institutional Animal Care and Use Committee 
(IACUC) at Drexel University College of Medicine. MMTV-PyMT mice mammary fat 
pads/tumors were isolated at indicated ages and were lysed or fixed for IHC. Histology 
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was performed as previously described [60]. B6.129-Ogttm1Gwh/J females used for fat 
pad injections have been previously described [18] and were obtained as a kind gift from 
S Jones (University of Louisville). Mice were injected directly into the mammary fat pad 
with Ad5-CMV-GFP or Ad5-CMV-Cre (2.7 × 107 PFU, from the Baylor College of 
Medicine). B6.129-Ogttm1Gwh/J females were a kind gift of S Jones (University of 
Louisville) and were previously described [18] Mice were injected directly into the 
mammary fat pad with Ad5-CMV-GFP or Ad5-CMV-Cre (2.7 × 107 PFU, from the 
BaylorCollege of Medicine) post parturition daily for three days. Animals groups were 
not blinded. Histology was performed as previously described [60]. 
PYMT Lysate and Tissue  
Tissue was collected from mammary fat pads of MMTV-PyMT female mice at 4, 8, 12 
and 14 weeks of age. Tissue was processed for whole cell lysate as described previously 
[76, 207] and was used in western blotting procedures as described above.  
Lactate Assay  
Lactate production was measured with the Lactate Assay Kit II (BioVision, Milpitas, 
CA), by assaying conditioned media, according to the manufacturer’s protocol.  
DCF-DA Assay  
. Total cellular ROS was assessed using 2,7-dichlorodihydrofluorescein diacetate 
(DCFH-DA) (Sigma). MDA-MB-231-control and MDA-MB-231-SREBP-1 cells 
expressing control or OGT shRNA plasmids were seeded at a density of 100,000 cells per 
well in a 6 well plate and following 48 hours of growth, cells were trypsinized, washed 
with phosphate buffered saline, and re-suspended in PBS containing 10µM DCFH-DA. 
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Following a 30-min incubation, cells were collected by centrifugation, re-suspended in 1x 
PBS, and analyzed by flow cytometry using a Guava Easy-Cyte Mini flow cytometer. 
Mean fluorescence was normalized to final cell count also determined by FACS analysis.  
Soft Agar Colony forming Assay 
Media containing 1% agarose was coated and solidified in a 6 well plate. 10,000 cells per 
condition were mixed with 0.3% agarose and plated on top of bottom agarose layer. After 
growth in standard incubator conditions (20% O2, 5% CO2, 95%, 37 degree C) for 21 
days, cells were fixed and stained p-Iodonitrotetrazolium (INT)- violet and colonies were 
counted.  
BODIPY upake  
4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Hexadecanoic Acid 
(BODIPY FL-C16) was purchased from Invitrogen. Briefly, cells were trypsinized with 
0.05% Trypsin and quenched with 1% Fatty Acid Free Albumin/PBS. Cells were then 
counted and washed in warm PBS and incubated with BODIPY FL-C16/1% BSA/PBS 
solution at room temperature for 20 minutes. Cells were then washed in cold PBS three 
times, resuspended in 1ml PBS and FACS (using a Guava Easy-Cyte Mini flow 
cytometer) was used to quantify mean Green Log fluorescence, gating for viable cells. 
Fluorescence was then averaged and presented as relative mean normalized to control 
cells +/- SE.  
FAME Assay 
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Cells were infected with control lentivirus or lentivirus targeting OGT. After 48 hours of 
selection, cells were incubated for 24 hours in media containing 10mM 13C 
Glucose/Glucose Free DMEM. Equal numbers of cells were then collected from each 
sample, lipids extracted using a standard chloroform/methanol procedure previously 
described [208]. The chloroform fraction was dried under nitrogen and redissolved in 
methanol/toluene. Derivitization occured after addition of acethylchloride (14mM) and 
butylated hydroxtoluene (0.45mM) and heating at 100 degrees C for one hour. Post 
cooling, 0.56 M aqueous sodium carbonate was missed with the solution which was 
prepared for injection into Agilent 5975C GC-MS system equipped with a single 
quadrupole mass detector by centrifugation and transfer to appropriate glassware... A 
polar DB-5 column was used for chromatography and data was focused on measurements 
of palmitate. Mass spectrometry data was normalized to an internal control and to control 
samples and represented as a relative value. Data was analyzed using MSD ChemStation 
software from Agilent Isocor, written for the Python programming environment to 
account for natural 13C abundance. Analyses were performed by Joyce Lee and Dr. 
Kathryn Wellen. 
Crystal Violet Staining  
MCF10A or MMTV-Myc cells were plated at a density of 200,000 cells per well in a 6 
well plate. After 24 hours they were treated with the indicated concentrations of Ac-5s-
GclNAc or vehicle control (DMSO) for 48 hours. Cells were then stained with 0.5% 
Crystal violet (Hexamethylpararosaniline chloride) (Sigma). MDA-MB-231 cells were 
made to express the indicated plasmids (either infected with lentivirus- control or OGT 
shRNA or retrovirus – control or SREBP-1, then selected) and plated at a density of 
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20,000 cells per well in a 6-well plate, grown for 8 days then crystal violet stained as 
indicated. Quantification of staining was performed by suspending dried stained wells 
with 1ml of 1% sodium deoxycholate and read at 590nm in a spectrometer.  
Immunofluorescent Staining and 3D culture  
MDA-MB-231-control or MDA-MB-231-SREBP-1 cells expressing control or OGT 
shRNA, in respective media containing 2% Matrigel, were plated at a density of 5,000 
cells per well in an 8-well chamber slide (BD Biosciences) coated with ~50 μl of 
Matrigel. Cells were fixed using 4% formalin and Immunofluorescence of 3D structures 
was performed using antibodies to cleaved caspase-3, SREBP-1 or OGT then stained 
with 4′,6-diamidino-2-phenylindole and fluorescent secondary antibodies coupled with 
Alexa-Fluor dyes (Molecular Probes, Carlsbad, CA, USA). Confocal analysis was 
performed by using the Leica DM6000B Confocal Microscope (Leica). Images were 
generated containing scale bars using the Leica Imaging Software (Wetzlar, Germany) 
and converted to Tiff format.  
Immunohistochemistry (IHC) 
Tissues were fixed and paraffin embedded. Slides were first deparaffinized using 2x 10 
minutes xylene, then a series of ethanol consisting of 3x 5minutes each; 100%, 90%, 70% 
and ddH20.  Antigen retrieval consisted of heating slides in 1x citrate buffer pH 6.0 for 
30 minutes in a pressure cooker/steamer then cooled f or 30 minutes. After 3x 3 minute 
washes in 1x PBS, internal peroxidase quench was achieved using 3% Hydrogen 
Peroxide/tap water followed by 3x 1x PBS washes. Tissue was then blocked in 5% horse 
serum/1x PBS for 90 minutes at room temperature. Primary antibody was made in 
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blocking serum and incubated on tissue overnight at 4 degrees in humidified chambers. 
Prior to secondary antibody addition, using VECTASTAIN Universal Elite ABC HRP 
Kit (Vector Laboratories) tissues were washed 3x in 1x PBS. This was wash was 
performed post-secondary antibody as well.  The ABC kit was then used following 
manufacturers’ instructions and subsequently DAB Peroxidase (HRP) Substrate Kit 
(Vector Laboratories). Slides were then washed in tap water and dehydrated following 
reverse deparaffinization protocol, mounted and visualized by microscopy.   
Statistical Analysis 
All results shown are results of at least three independent experiments and shown as 
averages and presented as mean ± s.e. P-values were calculated using a Student’s two-
tailed test (* represents at least P-value 0.05, where indicated *p-value ≤ 0.05 or **p-
value ≤ 0.01 or as marked in figure legend). Appropriate sample size was chosen to 
achieve significance using this analysis. Statistical analysis of growth rate of mice was 
performed using ANCOVA. *p-value < 0.05. 
Glucose Uptake 
Cells were plated at a density of 100,000 cells/well in a 6 well plate. After 48 hours, 
media was collected and cells were counted using the Guava Easy Cyte Plus system and 
CytoSoft (version 5.3) (Millipore Corporation). Control media and each sample were 
measured on an Accu-chek Active (Roche) Glucose consumption was calculated by 
subtracting sample measurement from control and normalizing to cell number.  
Mammary Fat Pad  
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 Virgin or pregnant females were injected in the all mammary fat pads (virgin- inguinal 
fat pad) with Adenoviral Cre Recombinase or Adenoviral GFP daily for three days post-
wean or post-parturition as indicated in figure legends or text. Offspring fed ad lib for 21 
days. Mammary fat pads were then collected and protein was extracted for western blot 
analysis or for immunohistochemistry staining after paraffin imbedding. Pup weight was 
recorded over time and compared between litters fed from OGT WT and OGT -/- female 
mothers.  
Essentiality determination using Project Achilles  
The Project Achilles database consists of shRNA depletion scores from a pooled hairpin 
library tested on a large collection of cancer cell lines. Briefly, an essentiality score is 
available for a given gene in a specific cell line if multiple targeting hairpins exhibit 
similar enrichment or depletion patterns in vitro. Details regarding score calculation have 
been previously reported [209, 210]. As this approach maximizes the selection of the “on 
target” shRNAs, the score provides a quantitative measure of gene importance for cell 
viability and/or proliferation. For identifying genes with similar essentiality value to OGT 
in the specific context of breast cancer cell lines, we used the openly available Morpheus 
platform (Broad/MIT). The approximately 5,700 genes present were ranked versus OGT 
using the “nearest neighbor” analysis. Analyses were performed by Dr. Mircea Ivan.   
 
CHAPTER 7: DISCUSSION AND FUTURE DIRECTIONS 
7.1 Discussion 
7.1.1Significance of OGT/O-GlcNAcylation 
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As indicated by each new mechanism of signaling revealed, the regulation of cellular 
responses and behavior aimed at cell survival and sustenance form incredibly complex 
networks, often influencing broad cellular processes. Layers of regulation of protein 
expression exist not only at the level of production, through transcription and translation, 
but also in maintenance and function of protein via mechanisms which control activity (if 
the protein is an enzyme) and stability / degradation. The pivotal role that post-
translational modifications play in controlling proteins and therefore signaling and 
cellular behavior has become evident with most efforts aimed at understanding common 
PTMs like phosphorylation. The appreciation of a seemingly unnoticed glycosylation has 
grown as techniques to examine and quantify less abundant modifications have become 
available.  
As mentioned above, a role for OGT in the etiology or maintenance of various diseases 
has appeared over the last two decades through the efforts of many groups [10]. Our lab 
has characterized the elevation of OGT in breast and prostate cancer and uncovered that 
the presence of OGT in breast cancer is required for cell viability, invasion and 
metastasis [21, 59]. We have also detailed the promotion of angiogenesis, invasion and 
metastasis in prostate cancer by OGT [60]. In this thesis we focused on how OGT protein 
is elevated in breast cancer in an attempt to understand why this finding is so universal 
across breast cancer subtypes and has also been observed in many other cancer types. We 
also aimed to determine if OGT was responsible for promoting other metabolic 
phenotypes of cancer extending beyond glycolysis which we recently linked to OGT and 
O-GlcNAcylation in breast cancer [21]. Our findings reveal that OGT expression 
required signaling through PI3K/AKT/mTOR. Downstream of mTOR, c-Myc was found 
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to be both required and sufficient to promote OGT elevation and an increase in global O-
GlcNAcylation. The chaperone HSP90 interacts with OGT and acts to stabilize OGT 
protein only in the presence of c-Myc and we hypothesize that this forms a positive feed-
forward loop due to the fact that O-GlcNAcylation on c-Myc functions to block its 
degradation [177]. Non-transformed mammary epithelial cell line MCF10A did not offer 
any response to OGT inhibition. However, breast cancer cells containing elevated c-Myc 
levels (MTEC-MYC) were susceptible to OGT pharmacological inhibition and induced 
apoptosis upon treatment in Ac-5sGlcNAc. With respect to the other goal of this thesis, 
we found that decreasing OGT results in a downregulation of many lipid metabolites. We 
pursued the idea that OGT could promote lipid synthesis in breast cancer cells and 
determined that OGT is required for SREBP-1 nuclear and precursor protein expression 
as well as the expression of many of its transcriptional targets. OGT enhances expression 
of the lipid synthesis promoting transcription factor SREBP-1 by suppressing AMPK 
activation. OGT inhibition activates AMPK which then directly phosphorylates SREBP-1 
and acts to decrease its expression. OGT suppression also increases the interaction 
between SREBP-1 and its E3 ligase FBXW7, potentially through GSK3β, a stipulation 
that needs to be investigated further. We had previously shown that OGT inhibition 
results in breast cancer cell death and attributed some of that effect to a role of OGT in 
cancer, the promotion of glycolysis through HIF1α [21]. Here, we show that decreases in 
SREBP-1 also contributes to apoptosis induced in response to OGT suppression. 
Restoring SREBP-1 protein expression to basal levels after OGT depletion significantly 
rescued cancer cell viability in vitro and tumor growth in vivo. Due to the similarity in 
lipid synthesis in breast cancer and in lactation in the breast, we also examined OGT in 
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this context. ogt deletion in vivo in B6.Ogt-loxP/loxP female mice results in decreased 
expression of lipogenic genes and decreased lipid droplet content in lactating mammary 
glands. Deletion of ogt, both at the time of weaning (late lactation) and at parturition 
(beginning of lactation), results in decreased expression of SREBP-1 and FAS as 
measured by IHC and/or western blot analysis. We also saw changes in signaling factors 
related to lactogenesis, milk production and β Casein protein production when ogt was 
deleted at parturition. The changes in pup litter weight of those fed from dams where ogt 
was deleted compared to control fed pups indicated that pups received less 
nutrients/calories contributing to their mass, either in the form of lipids or protein.  This 
could result from decreases in signaling that is required during activation of lactation 
such as upstream RTKS or more directly through SREBP-1. Beyond lipid regulatory 
processes, OGT affected expression of the milk protein β Casein. The mechanism by 
which this occurs requires further investigation as OGT could be acting on STAT5 
signaling which is known to regulate Casein. It is also important to more solidly 
determine if the changes seen are due to a block in lactogenesis.  
The ultimate goal of identifying elevated expression in cancer is to recognize novel 
biomarkers and therapeutic targets. We feel from the above work and the body of 
literature surrounding OGT and O-GlcNAcylation in cancer that the importance of this 
post-translation modification and this enzyme can be appreciated. Demonstrations of the 
requirement of OGT for cancer cell survival show potential utility in targeting this 
enzyme.  
7.1.2Targeting OGT  
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Various studies demonstrate a therapeutic window may exist to specifically target OGT 
and O-GlcNAcylation in cancer cells [76, 177, 211].  A number of novel chemicals have 
been developed to target OGT and reduce O-GlcNAcylation in mammalian cells. 
Namely, small molecule OGT inhibitors [212] and UDP-GlcNAc salvage pathway 
analogs [213].  In the past 10 years, Walker and colleagues [212, 214] have developed a 
number of OGT inhibitors aimed at providing insights to the biological and structural 
function of the enzyme in mammalian cells. Namely, the commercially available small 
molecule inhibitor ST045849, has been recently shown to stimulate cell death in prostate 
cancer cells when used in combination with alanine amidotransferase inhibitors [211].   
Vocadlo and colleagues [212], have identified a biosynthetic thiosugar, Ac-5SGlcNAc, 
that can be salvaged in cells yielding a nucleotide sugar analog that acts to inhibit OGT. 
Interestingly, these OGT inhibitors have been shown to reduce breast and prostate cancer 
phenotypes including cell growth and invasion, and increase metabolic stress and 
apoptosis via reducing expression of potent oncogenes such as FOXM1, c-MYC and 
HIF-1αβ [59, 60, 76, 177, 207]. In this thesis we also show that Ac-5sGlcNAc treatment 
results in decreased expression of SREBP-1 and lipogenic enzymes. More recently, the 
PI3K inhibitor, GDC-0941 demonstrated synergy with OGT inhibition to sensitize 
ovarian cancer cells and induce apoptosis in vitro [215]. The chemosensitizing effects of 
PI3K pathway inhibition with metabolic defects observed when targeting OGT may 
provide a promising combinatorial strategy.  
Little data exists to predict potential toxicity of targeting OGT using pharmacological 
inhibitors as a therapeutic strategy to combat cancer growth. Our lab and others have 
demonstrated through xenograft studies that RNAi inhibition of OGT results in decreased 
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tumor growth in vivo, however systemic administration of an O-GlcNAcylation inhibitor 
and its potential toxicities to various tissues has yet to be explored. We can postulate that 
systemic inhibition of OGT with a specific inhibitor may result in adverse events in 
normal cells with high OGT expression such as the insulin secreting cells of the pancreas.  
Alejandro and colleagues [20] demonstrated that β-cell specific ogt genetic deletion at 
embryonic day 13.5 results in mice having β-cell failure and diabetes. OGT deficient β-
cells displayed loss of mass and function, in part, due to elevated ER stress induced-
apoptosis, much like what was seen in breast cancer cells upon OGT inhibition [76]. 
However, ogt ablation in mature β-cells in 12 week old mice, had no effect on β-cell 
mass and mice did not develop diabetes.  This study highlights that adult tissues may not 
be as sensitive to O-GlcNAcylation inhibition when compared to developing tissues in 
mammals as well as the importance of understanding the various and complex roles of 
OGT in adult tissue.  
 Other potential toxicities may exist in tissues of the brain, as O-GlcNAc is found 
to be abundant within the brain and decreased O-GlcNAcylation correlates with 
Alzheimer’s phenotypes, potentially through direct modification of tau which is 
decreased in AD patient brain tissue [46]. The review by Yuzwa et. al. highlights recent 
work in which pharmacological means to increase levels of O-GlcNAc in the brain 
results in protective effects in mouse models of AD [46]. Inhibitory effects on neuronal 
excitability were seen when ogt was genetically deleted in AgRP neurons [216]. The 
ablation of ogt in this cell type protected the animals from diet-induced obesity and 
diabetes showing the complex dynamics of O-GlcNAc in the brain. With this in mind, 
any negative impact of inhibition of OGT in this tissue could be strategically avoided 
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through the development of pharmacological OGT inhibitors that are incapable of 
crossing the blood brain barrier. With significant efforts, OGT may prove to serve as a 
therapeutic target in breast and several other cancer types and will hopefully  confirm and 
validate the substantial anti-tumor effects we and other see when OGT is targeted 
genetically.  
7.2 Future Directions 
From the data presented here we hypothesize that OGT inhibition may synergize with 
HSP90 inhibitors as well as targeted therapies to lipogenesis. As mentioned previously 
more than a dozen HSP90 inhibitors are currently at least beginning clinical trials. HSP90 
acts to inhibit the degradation of a variety of cancer associated proteins and OGT/O-
GlcNAcylation promotes expression of many important oncogenes [52, 217]. We feel 
that the broad reaching effects of each inhibitor alone could, in combination, lead to a 
highly anti-tumor effect. There are multiple inhibitors available that serve to inhibit 
lipogenic enzymes at different points in the pathway.  Although the requirement of 
lipogenesis has been well chronicled in a variety of cancer tissues, inhibition of this 
process as a means of therapy has proved challenging. Much focus has been concentrated 
on factors upstream of SREBP-1 such as EGFR, mTOR and P13K [181] however FAS 
and ACLY inhibitors do exist. Genetic inhibition of lipogenesis downstream of SREBP-1 
favors the use of inhibitors against enzymes such as FAS and ACLY for the treatment of 
cancer. Compounds targeting FAS such as such as cerulenin, C75 and orlistat 
demonstrated effective inhibition of cancer cell growth/survival but resulted in 
unintended consequences of decreased food intake and body weight in animal studies 
which ultimately halted their prospects as potential cancer therapeutics [112]. ACLY 
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inhibitors (hydroxycitrate, SB-201076, SB-204990 and Compound 9 aka BMS-303414) 
have demonstrated more potential as therapeutic agents against obesity and dyslipidemia 
as in vivo animal studies showed drastic decreases in plasma triglycerides, cholesterol 
and in some cases glucose along with weight loss or prevention of weight gain in high-fat 
fed animals [218]. We propose that OGT inhibition may serve as an alternative strategy 
of targeting lipogenesis. Also, combination therapy may provide synergistic effects 
thereby potentially decreasing negative consequences of the above inhibitors, such as 
dramatic weight loss, while still enacting the same anti-tumor results seen with genetic 
inhibition studies. Although insufficiently studied here, our metabolic data points to an 
increase in the process of β-oxidation as measured by levels of carnitine metabolites 
when OGT was suppressed in breast cancer cells. Within the realm of lipid metabolism, it 
would be interesting to pursue the idea that OGT inhibition upregulates this process 
before eventually activating apoptosis. It makes sense that the decrease in glucose uptake 
and activation of AMPK induced by OGT inhibition would trigger catabolic pathways in 
an attempt to generate energy and promote survival. This could be tested through the 
addition of radiolabeled fatty acids (palmitate or oleate) to MDA-MB-231-control and 
MDA-MB-231-shOGT cells and conversion to labelled  CO2 can be quantified via 
scintillation counting as a measure of fatty acid oxidation. This could also be addressed 
through use of the Seahorse Bioscience technology which allows for measurement of 
fatty acid oxidation as a readout of oxygen consumption rate and can distinguish between 
use of exogenous and endogenous sources. If we confirm that survival post OGT 
inhibition is prolonged through activation of β-oxidation, an alternative anti-tumor 
strategy could be to target β-oxidation in conjunction with OGT. Another major area of 
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lipid metabolism that remains uncharted in relation to OGT and O-GlcNAcylation is 
cholesterol. As presented here, OGT regulates SREBP-1 via AMPK. AMPK also 
regulates SREBP-2 which plays a major role in transcriptionally controlling cholesterol 
synthesis. It is possible that OGT may also affect this transcription factor which is 
processed through the same means as SREBP-1 in terms of maturation.  
Due to the change in enzymes regulating production of acetyl-CoA (data in this thesis 
and unpublished data), it is reasonable to hypothesize that acetylation is linked to OGT 
and O-GlcNAcylation. We have shown here that ACLY (citrate to acetyl-CoA) is 
positively regulated by OGT and have also found that ACSS2 (acetate to acetyl-CoA) is 
regulated similarly (data not shown) in breast cancer cells. Not only do we believe that 
OGT promotes production of acetyl-CoA in breast cancer, we have recently demonstrated 
that OGT negatively regulates the tumor suppressor deacetylase SIRT1 [199]. The 
consequence of suppression of SIRT1 by expression of OGT in breast cancer was found 
to be the promotion of FOXM1 and invasion, however this data combined with our 
knowledge of acetyl-CoA producing enzymes implies much broader implications in gene 
expression especially if other sirtuins are found to respond to OGT modulation. Since 
acetyl-CoA contributes to the production of UDP-GlcNAc and is therefore needed for O-
GlcNAc modification, the network between these factors becomes more complex. 
OGT may play an important role in cellular aging.  It has long been understood that 
steady declines in cellular function results in onset and progression of various diseases 
and likelihood of the development of disease dramatically increases with age. Caloric 
restriction (CR) is the only recognized intervention that is known to extend both mean 
and maximal lifespan [219]. CR also delays onset of age-related diseases such as 
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diabetes, neurodegenerative disease and cancer. CR is defined as reduction in caloric 
intake without malnutrition (generally encompassing an intake of 20-40% less calories 
than a normal diet) [220]. Many cellular changes occur in CR cells that may contribute to 
life-span extension and anti-cancer properties. These include decreases in growth factors, 
anabolic hormones, inflammatory cytokines, oxidative stress and enhanced autophagy 
[221]. A more specific molecular definition of CR mimetics was recently described that 
includes: interventions that elicit a) the induction of autophagy, b) favoring deacetylation 
of proteins within the cell through decreasing cytosolic acetyl-CoA and/or induction of 
expression or activity of deacetylases which catalyze removal of acetyl groups from a 
range of proteins [222]. Since OGT inhibition causes both decreases in enzymes that 
promote acetyl-CoA production and increases in at least one sirtuin, we believe that OGT 
inhibition could mimic caloric restriction. It would be very interesting to determne if 
other characteristics of CR mimetics are associated with OGT and O-GlcNAc such as 
autophagy, especially because of the known links between OGT and AMPK and 
autophagy’s relationship with AMPK [156]. Overall there are many unexplored 
connections between OGT and cellular and organismal biology that can be pursued.  
Despite the remaining unknowns, advancements in our ability to detect the O-GlcNAc 
modification as well as a persistent interest in metabolic disorders and a renewed interest 
in classifying cancer as such have brought light to the importance of this small sugar 
post-translational modification. OGT and O-GlcNAcylation may serve clinically useful 
as either a biomarker or as a therapeutic avenue in several diseases in the near future. 
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